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1 Introduction
1.1 Gene therapy
The basis for gene therapy is to change the expression of selected genes in an
attempt to treat, cure or prevent disease. For this purpose, nucleic acids have to be
delivered into target cells to turn on or restore gene function (“gain of function”) or to
suppress specific gene functions (“loss of function”). Gene replacement strategies
typically aim at transduction of double-stranded DNA into the cell nucleus, whereas
gene modulating approaches involve the transfer of either antisense oligonucleotides
(AS-ON) (1), ribozymes (2) or small interfering RNA (siRNA) (3) into the desired cell
or tissue.
Although gene therapy has not yet been established as standard treatment, it has
already been applied in more than one thousand clinical trials, most of them (65 %) in
the field of cancer therapy. The most common strategies employed there were
immunotherapy and enzyme/prodrug approaches. Other gene therapy trials
addressed monogenic diseases (Hemophilia A and B, sickle cell disease, cystic
fibrosis, severe combined immunodeficiency syndrome (SCID)) and DNA vaccination
(4). However, the biggest hurdle that still limits therapeutic applications of genes is
the merge of efficient delivery and therapeutic safety concerns. Hence, gene therapy
holds tremendous promise for a broad spectrum of clinical applications, provided that
appropriate gene vector systems are available.
Two general approaches have been used for gene delivery: those involving viral
vector systems and those utilizing lipid- or polymer-based DNA complexes (nonviral
vector systems).
1 Introduction 7
1.2 Viral and nonviral vectors for gene delivery
1.2.1 Viral vectors
Viruses have a natural ability to infect host cells, and hence they offer an excellent
means of introducing foreign DNA sequences into cells for gene therapy (5). It has
been shown that binding of a single virus particle can be sufficient to infect the host
cell (6). This is the reason why more than 70 % of current clinical trials for gene
therapy employ viral vectors.
A number of different viruses have been adapted as vectors for gene therapy, mainly
retroviruses and adenoviruses. Since viral particles differ in their mode of infection
and reproduction, their biological characteristics strongly influence their applicability
as gene delivery vehicles. Good progress has been made to modify viruses by
removing certain viral genes associated with pathogenic function and altering viral
tropism. Furthermore, viruses have been rendered replication-defective in order to
prevent viral dissemination and reinfection.
In general, viral vectors are highly effective in gene transfer, the main weakness,
however, is safety (7). Application of retroviral vectors, for example, can cause
insertional oncogenesis resulting from random retroviral integration (8). Furthermore,
any virus used as a vehicle for the delivery of genetic material can incite an intense
inflammatory or immune response following administration. Since rather high doses
of virus are commonly used for efficient therapy, adverse effects can lead to a
catastrophic outcome. In 1999, a patient died following infusion of a high dose of
adenoviral vector (9;10). This was the first death that has been directly attributed to
the effects of the gene therapy.
1.2.2 Nonviral vectors
Nonviral gene delivery has several advantages over viral vector systems, the most
important being their low immunogenicity which allows repeated applications. This is
due to the fact that nonviral vectors present much less immunogenic proteins or
peptides compared to viral vectors (11). Furthermore, they offer easy synthesis and
production at low cost as well as high flexibility regarding the size of the genetic
material that may be delivered. Because nonviral systems do not show this inherent
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selectivity of cell surface binding and internalization (tropism) characteristic of
viruses, they can typically be used in a more universal fashion. Furthermore,
production by chemical synthesis allows various modifications and easy manipulation
so that nonviral vectors can be engineered for cell-specific and enhanced DNA
delivery. However, the major drawback of nonviral vector systems is that they are
generally many orders of magnitude less efficient than viral vectors, which is
currently only partly compensated by the application of high amounts of DNA.
For systemic administration, nucleic acids have to be protected from enzymatic
digestion. Therefore, complex-based gene delivery vehicles have been developed.
They are based on polymers or lipids, which bind DNA to form polymer/DNA
complexes or lipid/DNA complexes called polyplexes or lipoplexes, respectively.
Polycationic carriers include natural DNA binding molecules like histones or
protamines, chemically synthesized polyaminoacids, e. g. polylysine, or other
polycationic polymers (12). More recently, polyethylenimine (PEI), a synthetic
polymer with a high cationic charge density, has been demonstrated to be a highly
efficient and versatile vehicle for the delivery of DNA and RNA both in vitro and in
vivo (13).
1.3 Gene delivery with PEI polyplexes
In 1995, it was first reported on the ability of PEI to successfully deliver genes and
oligonucleotides both in vitro and in vivo (14). PEI polymers can be synthesized with
a linear or a branched topology and are available in a wide range of molecular
weights.
PEI is the organic molecule with the highest charge density potential, since every
third atom is an amino nitrogen that can be protonated. Ionic interaction between the
positively charged amino groups of PEI and the negatively charged phosphates of
nucleic acids leads to complexation and subsequent formation of small particles
called polyplexes. These compact particles can then enter the cells via natural
processes like endocytosis.
By condensing the DNA, PEI provides protection against physical and biochemical
degradation of the nucleic acids not only in the extracellular space but also inside the
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cell. For efficient complexation, a large excess of PEI is needed yielding polyplexes
with a net positive surface charge and leaving a considerable amount of PEI free in
solution. Although PEI polyplexes mediate efficient gene delivery in vitro, they are
typically found to exhibit strong cellular and systemic toxicity in vivo (15). Analysis of
purified PEI polyplexes showed that free PEI is the major cause of toxicity of PEI
polyplexes (16). Nevertheless, free PEI remains an essential factor for intracellular
gene delivery as it appears to enhance transfection efficiency (16).
Biophysical properties and cell biological behavior of these nanometric particles
depend on several factors, mainly the ratio of PEI to DNA used for complex formation
(calculated on the basis of PEI nitrogen and DNA phosphate and expressed as N/P
ratio) and the salt concentration during complex formation. At low salt concentrations
and/or N/P ratios above 6, small particles are formed, whereas aggregation is
observed in the presence of salt at lower N/P ratios (17;18). In vitro, transfection
efficiency is enhanced when large aggregated particles or polyplexes with high N/P
ratios are used. Increased cellular association (17) and improved intracellular
delivery were found to account for this effect (17;19).
Since the capability of viruses to efficiently deliver nucleic acids into the cell can be
attributed to their manifold strategies for breaking down various cellular barriers,
scientists have put much effort in emulating these features (20;21). The amino
groups of PEI polymers offer easy chemical modification and hence the possibility to
incorporate in a modular fashion several virus-mimetic components to provide
efficient cellular delivery characteristics. Several types of molecules have already
been linked to PEI, including proteins, peptides, sugar molecules and hydrophilic
polymers. They have been used in particular to reduce unspecific interactions, to
mediate cell-specific gene delivery and to improve endosomal release.
Introduction of foreign genes into cells is not natural, and hence cells have biological
barriers that protect them against invasion by foreign genes. Therefore, identifying
and overcoming each hurdle along the DNA entry pathway can improve DNA delivery
and hence overall transfection efficiency. Despite encouraging progress made in this
field, these barriers still represent a considerable challenge for nonviral vector
systems.
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1.3.1 Tissue targeting of PEI polyplexes
The first step in gene delivery entails the approach of the vector to the target cell
from the outside environment. Specificity for the target tissue is a key issue in gene
therapy and requires multiple modifications of the PEI/DNA polyplex.
Unmodified positively charged PEI polyplexes do not display the capability to
distinguish between target and non-target tissue but rather stick to any cell
membrane they reach. Therefore, systemic administration of PEI polyplexes into the
tail vein of a test animal is always associated with high gene expression in the lung
(22) and considerable systemic toxicity (23).
To prevent non-specific trapping and to reduce toxicity, PEI polymers have been
grafted with polyethylene glycol (PEG), a hydrophilic polymer, which shields the
positive surface charge but maintains the solubility of the particles. PEGylation has
been shown to prevent erythrocyte aggregation, reduce cytotoxicity and significantly
prolong circulation time (24). However, owing to decreased cellular binding of
PEGylated polyplexes gene delivery turned out to be less efficient (25;26). Moreover,
differences in the mode of internalization and intracellular routing or entrapment in
the endosomal compartment might account for this effect.
Some selectivity for tumor tissue can be achieved by administration of small
polyplexes displaying a neutral surface charge. Thus, passive accumulation of
PEGylated PEI polyplexes in distant tumors has been observed because of the
incomplete vasculature within the tumor. This mechanism, called “enhanced
permeability and retention effect” (EPR), enables the influx of polyplexes from the
blood into the tumor via leaky or incomplete blood vessels (27).
To introduce cell specificity and to restore the transfection efficiency of shielded
polyplexes, receptor-mediated endocytic pathways have been exploited for nonviral
gene delivery. For this purpose, targeting molecules have been attached to PEI
polyplexes to direct them to only those cells that express the corresponding receptor.
A number of ligands targeting receptors that confer specificity for a cell type (e. g.
asialoglycoprotein receptor for hepatocytes) or selectivity for a target cell
subpopulation (e. g. tumor cells overexpressing epidermal growth factor receptor)
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have been used to increase efficiency (28;29). These include proteins, peptides,
carbohydrates, vitamins or antibodies against cell surface receptors (Table 1).
RECEPTOR LIGAND TARGET CELLS REFERENCES
Asialoglycoprotein receptor Galactose hepatocytes (30-32)
Mannose receptor Mannose dendritic cells (33)
Folic acid receptor Folate various (34)
Transferrin receptor Transferrin different tumor cell lines (35)
EGF receptor EGF different tumor cell lines (36-38)
CD-3 Anti-CD-3 T cell-derived leukaemia
cells, activated PBMC´s
(39;40)
Table 1: Receptor-mediated targeting of PEI polyplexes to specific cell populations.
To date, transferrin-mediated uptake of gene transfer vehicles is among the best-
studied targeting systems. Covalent linkage of transferrin to PEI produced an up to
several-hundred-fold increase in transfection efficiency depending on the cell type
targeted (35).
Another targeting ligand that has been employed for PEI-mediated gene delivery is
the epidermal growth factor (EGF) since the epidermal growth factor receptor
(EGFR) is up-regulated in many human tumors (see 1.4).
1.3.2 Intracellular processing of PEI polyplexes
Upon binding to the target cell, polyplexes are internalized in order to deliver their
cargo. For successful gene delivery, several intracellular barriers then have to be
faced. These include cellular uptake, endosomal release and trafficking towards the
nucleus where the transgene can be transcribed. Figure 1 illustrates cellular uptake
and intracellular trafficking of PEI polyplexes carrying multiple functional domains to
overcome these obstacles.
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Figure 1: Schematic of cellular uptake and intracellular trafficking of shielded and targeted PEI
polyplexes. After binding to receptors on the plasma membrane, PEG-shielded and receptor-targeted
PEI polyplexes are mainly taken up into cells by receptor-mediated endocytosis. For efficient gene
delivery, polyplexes need to escape from the endosome and traffic towards the nucleus, enter the
nucleus and expose the DNA to the cell’s transcription machinery. Novel components for overcoming
these hurdles are being incorporated into synthetic vectors in order to enhance gene transfer
efficiency.
1.3.2.1 Endocytosis pathways mediating cellular uptake of PEI polyplexes
Despite various studies investigating the mechanisms of uptake and intracellular
trafficking (41-46), current understanding of the processes involved in cellular uptake
of PEI/DNA polyplexes is still limited.
In general, the types of endocytosis can be divided into clathrin-dependent and
clathrin-independent pathways (Figure 2). Clathrin-dependent endocytosis is initiated
by the formation of clathrin-coated pits yielding clathrin-coated vesicles and leads to
the formation of early and late endosomes which ultimately fuse with lysosomes (47).
Clathrin-independent endocytosis occurs via caveolin-dependent and caveolin-
independent endocytic pathways (also classified as raft-dependent endocytosis),
macropinocytosis or phagocytosis. Caveolae are smooth invaginations of the plasma
membrane associated with caveolin-1 (48) and enriched in cholesterol and
sphingolipids. They can be considered as a specialized form of lipid rafts.
Internalization occurs via a cholesterol-sensitive pathway forming caveolar vesicles.
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These then fuse with caveosomes which have been found to show a neutral pH (49).
Macropinocytosis is an actin-driven process forming large vesicles by the closure of
ruffling membrane domains (50). Phagocytosis is restricted to specialized cells
including macrophages that function to clear large pathogens or cell debris from the
circulation.
clathrin-
coated pits
raft dependent
clathrin
dependent independent
caveolae others
macropinocytosis
and
phagocytosis
Figure 2: Modes of internalization. Endocytosis can be divided into clathrin-dependent and clathrin-
independent pathways, the latter including caveolin-dependent and caveolin-independent endocytosis
(raft-dependent), macropinocytosis and phagocytosis. Clathrin-dependent endocytosis starts with
clathrin-coated pit formation and leads to the formation of endosomes. Caveolae are cholesterol-rich
invaginations of the plasma membrane containing caveolin-1. They are internalized via a cholesterol-
sensitive pathway forming caveosomes. Macropinocytosis is an actin-driven process forming large
vesicles by the closure of ruffling membrane domains.
To shed light on the mode of internalization of nonviral vectors, inhibitors specific to
the various endocytosis pathways have been applied in several studies (41-
43;46;51;52). Chlorpromazine – which has been shown to disturb intracellular clathrin
processing (53) – was used to inhibit clathrin-dependent endocytosis. Filipin III has
been employed to block caveolae/raft-mediated endocytosis since it complexes
membrane cholesterol and thus interferes with cholesterol-sensitive processes (54).
In order to elucidate which types of endocytosis are involved in the cellular uptake of
PEI polyplexes, recent studies reported on the close relation between particle size
and internalization pathway, however with inconsistent results. Rejman et al. (41)
proposed that particles < 200 nm are taken up via the clathrin-dependent mechanism
whereas larger particles (200-500 nm) enter the cells through caveolin-1-rich
vesicles. Other authors (51) claimed that large complexes (> 200 nm) are internalized
by macropinocytosis, medium-sized particles by clathrin-coated pits and small
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complexes (≤100 nm) via caveolae. This correlation between particle size and
uptake pathway is indeed plausible since some of these pathways are confined in the
size of their vesicles – e. g. clathrin-coated and caveolae-derived vesicles (47;49).
Large PEI polyplexes were also proposed to exploit non-endocytic pathways for
cellular entry since it was found that the high charge density of PEI polyplexes is
capable of inducing local membrane damage especially when large aggregates
interact with the plasma membrane (55). Nevertheless, all these hypotheses might
fail when decoding the uptake pathways of modified PEI polyplexes.
Much research is being conducted to identify the cellular structures involved in the
cellular uptake of PEI polyplexes. For complexes bearing a net positive surface
charge (unshielded PEI polyplexes), heparansulphate proteoglycans (HSPGs) –
negatively charged transmembrane proteins ubiquitously expressed on adherent
cells – were proposed to play a role as potential receptors mediating cellular polyplex
uptake (45;56;57). Recently, a more detailed model was hypothesized (43)
suggesting that syndecans might be involved as receptors for initial particle binding.
These HSPGs were postulated to subsequently trigger actin filament-mediated
engulfment (“phagocytosis”) of the polyplex. However, direct evidence for an
interaction of polyplexes with cell surface structures and the actin filament network
was still lacking.
Eukaryotic cells utilize the different endocytic pathways to internalize a variety of
substances and to accomplish different tasks. It is therefore conceivable that the
mode of internalization of PEI polyplexes affects their intracellular processing and
thus transfection efficiency as such. Rejman and coworkers recently addressed this
issue on the relative contribution of each pathway to gene transfer efficiency and
proposed that only the caveolae/raft-mediated pathway leads to efficient transfection
of branched PEI/DNA polyplexes (42). However, further evidence will be necessary
to unambiguously clarify the role of each pathway and its determinants in PEI-
mediated gene delivery.
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1.3.2.2 Endosomal release of PEI polyplexes
Internalized gene transfer complexes are mostly found in intracellular vesicles such
as endosomes. Due to the action of vesicular ATP-dependent proton pumps,
endosomal compartments undergo continuous acidification from the initial cell
surface pH (pH ~ 7), ultimately to that found in lysosomes (pH ~ 4.5). Subsequent
release of PEI polyplexes into the cytoplasm represents a major bottleneck for gene
delivery (58;59) since DNA must exit the vesicles before it is degraded in the
lysosomes. The high transfection efficiencies observed with PEI have been attributed
to its strong buffering capacity within the physiological pH range. This can be
explained by the so-called proton sponge effect: protonation of PEI´s ionizable amino
groups leads to chloride ion accumulation and subsequent osmotic endosome
swelling by influx of water which eventually causes rupture and enhanced escape of
the polyplex. Direct measurements of acidification, chloride accumulation, and
endosomal swelling support this hypothesis (19;44;60-62). However, release of PEI
polyplexes can be significantly hampered when using low molecular weight PEI (63)
or either small or purified PEI complexes at low DNA concentrations (16;17). To
overcome endosomal entrapment of polyplexes, inactivated adenovirus particles (64)
or membrane active peptides like melittin (65) have been incorporated into
polyplexes and significantly enhanced gene delivery.
For efficient nuclear import, the polyplexes have to travel towards the cell nucleus.
Since the cytoplasm contains a filamentous cytoskeleton network embedded in a
concentrated mix of soluble proteins and organelles, passive diffusion of large
molecules like DNA and polyplexes is highly inefficient (66). Little is known about the
transport processes which allow the polyplexes to enter the cell and reach the
nucleus. In order to unravel the dynamics of the processes involved, newly
developed single particle tracking techniques are being employed (6). First results of
such experiments indicate that once inside the cell, polyplexes are actively
transported to the perinuclear region (67). Based on the effect of microtubule
disrupting drugs on the intracellular transport of polyplexes, it was hypothesized that
the cellular microtubule network plays a pivotal role in the transfection process (67),
although it could not yet be elucidated whether this transport is mediated within
vesicles. Nevertheless, convincing evidence on the basis of dynamic data
1 Introduction 16
characterizing the movement of polyplexes inside the cell has not yet been
presented.
1.3.2.3 Nuclear import of PEI polyplexes
The nuclear membrane presents a major barrier to the entry of free and polyplex-
associated DNA from the cytoplasm (68). In several studies, less than 0.1 % of
plasmid DNA which had been injected into the cytoplasm was found to be transcribed
(69). In general, there are two paths to nuclear entry: one through the “nuclear pore
complex” (NPC) and one via nuclear disassembly that occurs during cell division.
Entry through the NPC may be passive or active. Passive diffusion through the NPC
is determined mainly by the size of the molecule: DNA of up to 300 bp and DNA
nanoparticles up to a diameter of 25 nm were found to traverse the NPC (70), since
their small size permitted nuclear uptake across the 25 nm nuclear membrane pore.
In polyplex-mediated gene delivery, the major path of nuclear entry seems to be via
nuclear disassembly during mitosis since dividing cells yield much higher transfection
efficiencies than postmitotic cells. For lipoplex- and polyplex-based transfections,
highest reporter gene expression levels have been recorded for cells in the
G2/M phase with a 30- to 500-fold increase as compared to G1 cells (71).
Interestingly, polymer-mediated transfection using linear PEI was far less dependent
on cell cycle compared to branched PEI (72). In order to enhance nuclear uptake,
signal-mediated active transport mechanisms have been explored for trafficking
vectors to the nucleus. Covalent coupling of a single nuclear localization signal (NLS)
peptide to a CMV-Luciferase gene led to an up to 1000-fold enhancement in
transfection efficiency presumably attributed to improved nuclear translocation by the
nuclear import machinery (73).
1.4 EGFR-targeting for cell-specific gene delivery
Epidermal growth factor (EGF) is a globular protein of 6.2 kDa consisting of 53 amino
acids that binds specifically and with high affinity (74) to the EGFR.
The EGF receptor (EGFR, also known as HER1 or ErbB1) represents one of the four
members of the ErbB receptor family of receptor tyrosine kinases. The ubiquitous
170 kDa membrane-spanning glycoprotein is composed of an N-terminal
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extracellular ligand binding domain, a hydrophobic transmembrane region and a
cytoplasmic domain which contains the tyrosine kinase (75).
EGFR activity controls proliferation, differentiation and cell survival of a wide range of
cell types. EGFRs can be detected both within and outside lipid rafts (76). This is
apparently an important regulatory mechanism since sequestration of the receptors
in non-caveolar lipid rafts inhibits ligand binding (77). However upon binding EGF,
EGFRs can migrate out of the raft membrane and undergo clathrin-dependent
endocytosis (76).
On the molecular level, EGF binding induces the dimerization of EGFRs (78) and the
trans-autophosphorylation of tyrosine residues in the cytoplasmic domain of EGFRs
which leads to subsequent internalization of the activated EGFR complex via clathrin-
dependent endocytosis (Figure 3) (79). After internalization, receptors can be sorted
to recycling endosomes from which they travel back to the cell surface. Alternatively,
they can be directed to lysosomes where they are degraded (80). The
phosphorylated tyrosines serve as docking sites for a number of adaptor molecules
that can initiate a plethora of signaling pathways, resulting in cell proliferation,
protection from apoptosis or transformation (81). Cytoplasmic signal transducers that
can be activated by the EGFR include, for example, MAPKs, Akt, the stress-activated
protein kinases (SAPKs) and JNK (81;82). In the nucleus, these signaling pathways
can initiate distinct transcriptional programs involving enhanced activity of the proto-
oncogenes c-jun and elk-1 (81). It has been shown that EGFRs localized both in the
plasma membrane and in the endosomal membrane can recruit effector proteins and
trigger such signaling pathways (83-85).
Recently, it was reported that EGFRs were exclusively internalized through the
clathrin pathway only when stimulated with low doses of EGF. At higher
(physiological) concentrations of ligand, however, EGFRs become ubiquitinated and
are partially endocytosed through a lipid raft-dependent route (Figure 3) (86;87). This
pathway does not contribute to EGFR signaling, but is preferentially associated with
receptor degradation (86;87).
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Figure 3: Epidermal growth factor receptor trafficking and signaling. EGF binding induces the
dimerization of EGFR and autophosphorylation in the cytoplasmic domain. Assembly of clathrin
proteins leads to the formation of clathrin-coated pits and subsequent internalization of the activated
EGFR complex. After internalization into early endosomes, EGFRs can be sorted to the recycling
endosome, from which they are transported back to the cell surface. Alternatively, EGFRs can be
directed to late endosomes/lysosomes to be degraded. Activated EGFRs further initiate several
downstream signaling pathways triggering cell proliferation etc. At high doses of EGF, internalization
can also occur via lipid rafts leading to EGFR degradation. This route does not contribute to EGFR
signaling.
Over the past years, the EGFR and its ligands have repeatedly been observed in the
nucleus of different cell lines and tissues including many human cancers (88-91). It
has been shown that binding of the cognate ligand is required for nuclear localization
and accordingly, the complete ligand–receptor complex was reported to be present in
the nucleus (92). The route(s) by which the EGFR or fragments of it move into the
nucleus have not been clearly elucidated yet. Although existing data do not discern
the function of this only recently discovered process, understanding of the
phenomenon might open up new possibilities to target nonviral vectors towards the
cell nucleus.
The EGFR is a tempting target for gene delivery since it is overexpressed in a wide
variety of human tumors, including cancers of lung, liver, breast, and also in
hepatocellular carcinoma (HCC). For example, HCC cells express EGFR levels of
approximately 3 x 105 receptors per cell (93). Moreover, the EGFR shows high
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affinity to its ligand EGF: 10 % of the receptors exhibit a dissociation constant (Kd) of
3 x 10-10 M and 90 % a Kd of 2 x 10-9 M (94). Because of these favorable
characteristics, the EGFR has been used as a target for cell attachment of
polyplexes. In particular, polylysine conjugates of anti-EGFR antibodies (95;96),
fusion proteins containing the EGFR ligand TGF alpha (97) and polycation
conjugates of EGF (36;37;98;99) or EGF-derived peptides (100-102) have already
been applied for EGFR-specific gene delivery. On the cellular level, such EGF-
containing polyplexes showed significantly increased cellular uptake (103) and
enhanced transfection efficiency compared to polyplexes without EGF.
Both unshielded and PEGylated EGFR-targeted polyplexes have proven successful
in improving gene delivery into EGFR-expressing cells (36). For systemic
administration however, shielding is inevitable to render the polyplexes less
susceptible to interactions with non-target tissue. Three different strategies were
pursued for the formation of PEGylated EGFR-targeted PEI polyplexes (36): (i) post-
PEGylation of EGF-PEI/DNA polyplexes, (ii) PEGylation of PEI/DNA polyplexes and
subsequent covalent attachment of the ligand EGF, (iii) complexation of DNA with a
mixture of PEI, PEG-PEI and EGF-PEG-PEI conjugates in a one-step-process.
Although the 6 kDa EGF ligand is rather small compared to the 20 kDa PEG shield,
all three formulations were able to mediate EGFR-specific gene transfer (36).
Recently, cryoconservable PEG-shielded and EGFR-targeted polyplexes were
engineered for tumor-directed gene delivery (37). They were formed by complexing
DNA with a mixture of linear PEI (LPEI, 22 kDa), PEG(20kDa)-PEI22 and a
conjugate where mEGF is linked to branched PEI (BPEI, 25 kDa) via a
heterobifunctional 3.4 kDa PEG spacer (strategy iii, see above). In vitro, these
EGFR-targeted polyplexes significantly enhanced gene transfer efficiency into human
EGFR-overexpressing HCC cells compared to non-targeted PEG-shielded
polyplexes. They were also able to target subcutaneous tumors after tail vein
injection into HCC xenograft bearing mice (37). Notably, no acute toxicity was
observed in any of the animals. These findings suggest that this strategy might be
considered a promising approach for the treatment of patients with HCC. However,
until now the process of EGFR-specific gene delivery has not been characterized in
detail.
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1.5 Objectives of this thesis
A detailed understanding how the nonviral vectors interact with cellular components
is a key aspect towards improving their design. Therefore, the aim of the present
work was to shed light on the cellular mechanisms of EGFR-targeted gene delivery.
Regarding these processes, it was focussed on the following issues:
Cellular uptake of EGFR-targeted polyplexes
Receptor-mediated uptake processes are known to be very fast. If specific binding
between complex-bound EGF and the EGFR indeed occurs, it can be assumed that
uptake of EGF(+) polyplexes proceeds much faster than that of non-targeted
complexes.
EGFR activation by EGFR-targeted polyplexes
Since EGFR activity controls proliferation and cell survival, the potential ability of
EGF(+) complexes to trigger EGFR activation of the target tumor cells might be of
relevance for therapeutic applications.
Cell cycle dependency of EGFR-targeted gene delivery
The EGFR and its ligands have repeatedly been observed in the nucleus of different
cell lines. If this route would also be available for EGFRs bound to EGF(+)
polyplexes, EGFR-targeted vectors might have the capability of transfecting
postmitotic cells.
Internalization mode of EGFR-targeted polyplexes
Little is known about the uptake processes of PEI polyplexes, their relative
contribution to efficient gene transfer and the factors influencing their significance.
Although much research has been conducted to elucidate the mechanisms of EGFR
internalization, the mechanisms involved in cellular entry and intracellular processing
of EGFR-targeted polyplexes have not been addressed so far.
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2 Materials and methods
2.1 Chemicals and reagents
2.1.1 Chemicals and reagents
Thymidine, nocodazole, EDTA, chlorpromazine, filipin III, DAPI, MTT and Hoechst
33342 were purchased from Sigma-Aldrich (Munich, Germany). PI, YOYO-1, Alexa
Fluor® 647 transferrin and Alexa Fluor® 488 cholera toxin subunit B (CTB) were
supplied by Molecular Probes (Leiden, Netherlands). Cell culture plates were
purchased from TPP (Trasadingen, Switzerland). The gel filtration columns
Sephadex G-10 HR10/30 and Sephadex G-25 superfine were obtained from
Amersham Biosciences (Germany). The cation-exchange column Macro-prep High S
10/10 was purchased from BioRad (Munich, Germany).
Recombinant murine epidermal growth factor (mEGF, MW = 6000) and human
epidermal growth factor (huEGF, MW = 6200) were obtained from Pepro Tech EC
Ltd. (London, Great Britain). The amounts of mEGF and huEGF were determined by
measuring the absorbance at 280 nm (1 mg mEGF = A280/3.1; 1 mg huEGF = A280/3).
Succinimidyl 3-(2-pyridyldithio)propionate (SPDP) was purchased from Sigma-
Aldrich. The amount of dithiopyridine linker conjugated to mEGF was determined
after reduction of an aliquot by dithiothreitol (DTT) followed by measurement at
340 nm (104).
α-Maleimide-ω-N-hydroxysuccinimide ester-polyethylene glycol (NHS-PEG-MAL,
MW = 3400) was obtained from Nektar Therapeutics (Birmingham, AL, USA). The
amount of reactive maleimide linker in the conjugates was determined by measuring
the absorbance before and after addition of dithiothreitol (DTT) at 300 nm.
The amount of mercapto-groups in mEGF-SH was determined by the Ellmans assay
(105).
The concentration of BPEI was measured by the trinitrobenzenesulfonic acid (TNBS)
assay (106).
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2.1.2 Polyethylenimine and polyethylene glycol conjugates
Branched PEI with an average molecular weight of 25 kDa (BPEI) and linear PEI with
an average molecular weight of 22 kDa (LPEI) were obtained from Sigma-Aldrich
(Munich, Germany) and Euromedex (Exgen 500, Euromedex, Souffelweyersheim,
France), respectively. They were dissolved in water, neutralized with HCl and
gelfiltrated on a Sephadex G-25 superfine column using 20 mM HEPES, 0.25 M
NaCl, pH 7.4. For complex preparation, PEI was used as a 1 mg/ml working solution.
2.1.2.1 Synthesis of PEG-PEI22
PEG-PEI22 conjugate was synthesized and purified as previously described by
Kursa et al. (107). Two different conjugates with molar ratios PEG (20 kDa)/LPEI of
0.9/1 and 1.7/1 were used.
2.1.2.2 Synthesis of mEGF-PEG-PEI25
Murine EGF-(2-pyridyldithio)propionate
A solution of 5 mg mEGF (lyophilized in 10 mM Tris buffer, pH 8.5) was reconstituted
in 2.5 ml of water and was dialyzed (dialysis tubing Spectra/Por 6, MWCO = 1000,
Serva, Heidelberg, Germany) overnight against 2 l of 20 mM HEPES pH 7.1,
degassed with argon. 3.36 mg (0.56 µmol) of mEGF in 3.5 ml was obtained and
mixed with 5 µmol of SPDP prepared in 1.5 ml 100 % ethanol. After 3 h at room
temperature, purification was performed by gel filtration on a G-10; HR10/30 column
with 20 mM HEPES pH 7.1, 20 % ethanol. The flow rate was 0.5 ml/min. The
conjugate was detected at 300 nm and eluted between 18 and 26 min. 4 ml of
conjugate consisting of 0.56 µmol of mEGF (3.36 mg) modified with 0.77 µmol of
dithiopyridine was obtained.
Murine EGF-SH
mEGF-PDP (0.56 µmol in 4 ml 20 mM HEPES pH7.1, 20 % ethanol) was mixed with
50 equivalents of DTT in 0.1 ml water and kept under argon. After 5 min at room
temperature, the reaction mixture was loaded on a gel-filtration column (Sephadex G-
10; HR10/30) and eluted with 20 mM HEPES pH 7.1, 20 % ethanol. The flow rate
was 0.5 ml/min. Detection at 280 nm showed that the product eluted between 17 and
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28 min. 5.5 ml of conjugate consisting of 0.28 µmol of mEGF and 0.51 µmol of
mercapto groups was obtained (molar ratio of 1/1.82).
PEI25-PEG-MAL
BPEI (1.6 µmol, hydrochloride salt, after gel filtration with Sephadex G-25 superfine)
was dissolved in 1.3 ml of 0.25 M NaCl and the pH was adjusted to 4.4. It was mixed
with 6.4 µmol NHS-PEG-MAL in 0.4 ml water for 1 h at room temperature. The
reaction mixture was adjusted to a final salt concentration of 1 M NaCl, loaded on a
cation-exchange column (Macro-prep High S; 10/10) and fractioned with a salt
gradient from 1 to 3 M NaCl in 20 mM sodium acetate buffer pH 4.5, over 10 min.
The flow rate was 0.5 ml/min. Detection at 240 and 300 nm showed that the PEI
conjugate eluted at 3 M NaCl. The amount of reactive maleimide-groups was
determined to be 0.94 µmol by MAL assay. The molar ratio of BPEI/MAL was 1/1.6.
Synthesis of mEGF-PEG-PEI25 (I)
mEGF-SH in 5.5 ml of 20 mM HEPES pH 7.1, 20 % ethanol equivalent to 0.28 µmol
of mEGF and 0.51 µmol of mercapto-groups was mixed under argon with PEI25-
PEG-MAL equivalent to 0.51 µmol maleimide. The pH of the reaction mixture was 6
and the salt concentration was 0.3 M NaCl. After 26 h at room temperature, the salt
concentration of the reaction mixture was adjusted to 0.5 M NaCl with 3 M NaCl,
loaded on a cation-exchange column (Macro-prep High S; 10/10) and fractioned with
a salt gradient from 0.5 to 3 M NaCl in 20 mM HEPES pH 7.1, over 60 min. The flow
rate was 0.5 ml/min. Detection at 280 nm showed that the conjugate eluted between
2.4 and 3 M NaCl. The resulting 10 ml of the conjugate was dialyzed (dialysis tubing
Spectra/Por 1, MWCO 6000 - 8000, Serva) overnight at 4 °C against 2 l HEPES-
buffered saline (HBS: 150 mM NaCl, 20 mM HEPES) pH 7.3, degassed with argon.
The amount of mEGF in the conjugate was determined to be 0.65 mg by
measurement at 280 nm. The amount of BPEI in the conjugate was determined to be
136 nmol by the TNBS assay. The molar ratio of mEGF/BPEI in the conjugate was
0.8/1.
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Synthesis of mEGF-PEG-PEI25 (II)
mEGF-SH (0.52 µmol) in 6 ml of 20 mM HEPES pH 7.1, 20 % ethanol was mixed
under argon with 0.52 µmol NHS-PEG-MAL (1.77 mg) in 0.1 ml water. After 10 min at
room temperature, 0.21 µmol of gelfiltrated BPEI in 0.5 ml of 0.25 M NaCl was added
under argon. After 20 h at room temperature, the salt concentration of the reaction
mixture was adjusted to 0.6 M NaCl with 3 M NaCl, loaded on a cation-exchange
column (Macro-prep High S; 10/10) and fractioned with a salt gradient from 0.6 to
3 M NaCl in 20 mM HEPES pH 7.1, over 60 min. The flow rate was 0.5 ml/min.
Detection at 280 nm showed that the product eluted at approximately 2.4 to 3 M
NaCl. The resulting 5 ml of conjugate was dialyzed (dialysis tubing Spectra/Por 1,
MWCO 6000 - 8000, Serva) overnight at 4 °C against 0.5 x HBS (75 mM NaCl,
10 mM HEPES, pH 7.3), degassed with argon, and concentrated by speed vac.
2.5 ml of the conjugate in HBS consisting of 0.95 mg (158 nmol) of mEGF modified
through PEG bridges with 2.4 mg (96 nmol) of BPEI with a molar ratio of 1.6/1 was
obtained.
2.1.2.3 Synthesis of huEGF-PEG-PEI25
Human EGF-(2-pyridyldithio)propionate
huEGF (2 mg, 323 nmol) was reconstituted in 0.5 ml water, degassed with argon.
The amount of huEGF was determined at 280 nm. The solution was added to 0.5 ml
of 200 mM sodium acetate buffer pH 6.0, 60 % ethanol while mixing vigorously. This
solution was mixed with 10 equivalents of SPDP in 0.5 ml of 100 % ethanol under
argon. The slightly acidic pH of the reaction mixture (pH 6) was necessary to
selectively modify the N-terminal amino group of huEGF. After 4 h at room
temperature, the functionalized peptide was purified by gel-filtration on a Sephadex
G-10 column, HR10/30, and eluted using 20 mM HEPES pH 7.1, 30 % ethanol. The
molar ratio of huEGF/dithopyridine was determined as described above. The purified
conjugate contained about 1.3 PDP groups per huEGF peptide.
Human EGF-SH
huEGF-PDP (0.24 µmol in 3.5 ml of 20 mM HEPES pH 7.1, 30 % ethanol) was mixed
with 50 equivalents of DTT in 0.1 ml water under argon. After 5 min at room
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temperature, the reaction mixture was loaded onto a gel-filtration column (Sephadex
G-10; HR10/30) and eluted using 20 mM HEPES pH 7.1, 30 % ethanol to remove
low molecular weight products. The amount of huEGF (0.52 µmol) was determined at
280 nm. The amount of mercapto-groups in the product was determined by the
Ellmans assay .The molar ratio of huEGF/SH was 1/1.3.
huEGF-PEG-PEI25
huEGF-SH (0.18 µmol in 4.5 ml of 20 mM HEPES pH 7.1, 30 % ethanol) was mixed
under argon with 0.18 µmol NHS-PEG-MAL linker in 0.1 ml water. After 10 min at
room temperature, 71 nmol of gelfiltrated BPEI in 0.5 ml of 0.25M NaCl was added to
the reaction mixture under argon. After 20 h at room temperature, the salt
concentration of the reaction mixture was adjusted to 0.6 M NaCl with 3 M NaCl,
loaded onto a cation-exchange column (Macro-prep High S; 10/10) and fractioned
with a salt gradient from 0.6 to 3 M NaCl in 20 mM HEPES pH 7.1, over 60 min. The
flow rate was 0.5 ml/min. Detection at 280 nm showed that the product (8 ml) was
eluted at approximately 2.4 to 3 M NaCl. The conjugate was dialyzed (dialysis tubing
Spectra/Por 1, MWCO 6000 - 8000, Serva) overnight at 4 °C against 0.5 x HBS,
degassed with argon and concentrated by speed vac. The amount of BPEI in the
conjugate was determined by the TNBS assay. 2 ml of conjugate in HBS consisting
of 0.26 mg (42 nmol) of huEGF modified through PEG bridges with 1 mg (40 nmol) of
BPEI with a molar ratio of about 1/1 was obtained.
2.1.3 Plasmid DNA
Plasmid pCMVLuc (Photinus pyralis luciferase under control of a cytomegalovirus
(CMV) enhancer/promoter) described in (108) was produced endotoxin-free by Elim
Biopharmaceuticals (San Francisco, CA, USA), Aldevron (Fargo, ND, USA) or
PlasmidFactory (PlasmidFactory GmbH & Co. KG, Bielefeld, Germany) or was
purified with the EndoFree Plasmid Kit from Qiagen GmbH (Hilden, Germany).
Plasmid pEGFP-N1 (encoding Enhanced Green Fluorescent Protein (EGFP) under
control of a CMV promoter) was purchased from Clontech Laboratories (Heidelberg,
Germany) or Elim Biopharmaceuticals.
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The plasmids pEGFP-Actin, pEGFP-Tubulin and pEGFP-Luc (encoding fusion
proteins of Enhanced Green Fluorescent Protein (EGFP) and human cytoplasmic β-
actin, human α-tubulin or luciferase, respectively, under control of a CMV promoter)
were purchased from Clontech Laboratories. All vectors contain a neomycin
resistance cassette (Neor), which allows stably transfected eukaryotic cells to be
selected using G418. pEGFP-Actin, pEGFP-Tubulin and pEGFP-Luc plasmids have
a size of 5.8, 6.0 and 6.4 kb, respectively.
2.2 Cell culture
Cell culture media, antibiotics, fetal bovine serum (FBS), G418 (geneticin) and
trypsin/EDTA solution were purchased from Invitrogen GmbH (Karlsruhe, Germany).
All cultured cells were grown at 37 °C in 5 % CO2 humidified atmosphere.
HUH-7 hepatocellular carcinoma cells (JCRB 0403; Tokyo, Japan) were cultured in
DMEM/F12 (1/1) with Glutamax I medium supplemented with 10 % FBS.
The mouse renal carcinoma cell lines Renca-EGFR (Renca cells stably cotransfected
with the plasmids pLTR-EGFR and pSV2neo) and Renca-LacZ (Renca cells stably
transfected with a construct encoding E. coli β-galactosidase) were cultured in RPMI-
1640 with Glutamax I medium supplemented with 10 % FBS and 0.5 mg/ml G418.
Both cell lines had been kindly provided by Winfried Wels, Georg-Speyer-Haus,
Frankfurt am Main, Germany.
HeLa human cervical carcinoma cells (ATCC CCL-2) were cultured in DMEM
supplemented with 10 % FBS.
2.3 Covalent labeling of plasmid DNA
Plasmid pCMVLuc was covalently labeled with the fluorophores Cy3 or Cy5 using the
Label IT kits (MIRUS, Madison, WI) according to the manufacturer´s instructions.
20 µg of DNA were diluted with 1 x Buffer A to a final volume of 195 µl. After addition
of 5 µl reconstituted Label IT reagent, the reaction mixture was incubated for 3 h at
37 °C. To precipitate labeled DNA, 550 µl of ice-cold 100 % ethanol and 22 µl of 3 M
sodium acetate were added. The solution was then mixed and placed at - 20 °C
overnight. Subsequent centrifugation at 16,000•g for 60 min (4 °C) allowed removal
2 Materials and methods 27
of unreacted label in the supernatant. The pellet was gently washed with ice-cold
70 % ethanol, centrifuged again and all traces of ethanol were removed. Labeled
DNA was allowed to dry for 5 min and finally resuspended in sterile HBG.
Cy3 (ε550nm = 150,000 l•mol-1•cm-1) and Cy5 (ε650nm = 250,000 l•mol-1•cm-1) content
were measured by absorption at 550 nm and 650 nm, respectively. DNA was
quantified by measuring the absorbance at 260 nm with the ratio of 260 nm/280 nm
serving as an index for DNA purity (≥1.8; ≤1.9). On average, one dye molecule was
bound per 50 bp to 100 bp, approximately.
2.4 Polyplex formation
In general, polyplexes were generated by condensing plasmid DNA encoding
luciferase or EGFP with PEI or PEI conjugates at a molar ratio of PEI nitrogen to
DNA phosphate (N/P) of 6, if not indicated otherwise. For this reason, plasmid DNA
and PEI or PEI conjugates were each diluted in the buffer indicated and rapidly
mixed by pipetting up and down 5 to 8 times. Polyplexes were allowed to stand for at
least 20 min at room temperature before use.
Unshielded DNA/PEI polyplexes were prepared freshly at a final DNA concentration
of 20 µg/ml by flash-mixing of plasmid DNA with PEI in HEPES-buffered glucose
(HBG, 5 % (w/w) glucose, 20 mM HEPES, pH 7.1), HEPES-buffered saline (HBS,
150 mM NaCl, 20 mM HEPES, pH 7.1), HBS ½ (2.5 % (w/w) glucose, 75 mM NaCl,
20 mM HEPES, pH 7.1) or OptiMEM at the indicated N/P ratio.
EGFR-targeted polyplexes (mEGF(+) complexes) were prepared by first diluting and
mixing EGF-PEG-PEI25 and PEG-PEI22 conjugates with free LPEI at a molar ratio
of EGF/PEG/PEI of 13 %/22 %/100 % in HBG. For the EGF-free polyplexes (EGF(-)
complexes), the PEG-PEI22 conjugate was mixed with free LPEI at a molar ratio of
PEG/PEI of 22 %/100 % in HBG. The PEI conjugate buffer solution was then mixed
with plasmid DNA diluted in HBG at an N/P ratio of 6 and a final DNA concentration
of 200 µg/ml. Complexes were incubated for 30 min at room temperature, snap-
frozen in liquid nitrogen, subsequently stored at - 80 °C and, before use, allowed to
stand for 30 min at room temperature after thawing.
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2.5 Measurement of particle size and zeta potential
Median particle size of polyplexes was determined by laser-light scattering using a
Malvern Zetasizer 3000HS (Malvern Instruments, Worcestershire, UK). Complexes
were generated and subsequently diluted to 10 µg/ml prior to measurement as
previously described (16).
For estimation of the surface charge, transfection complexes were diluted in 10 mM
NaCl to give a final DNA concentration of 2 µg/ml and the zeta potential was
measured as previously described (109).
2.6 Metabolic activity
Cells were seeded in 24 well plates at a density of 5 x 104 (HUH-7) or 3 x 104 (HeLa)
cells per well 24 h prior to the experiment. Cells were treated with different
concentrations of chlorpromazine or filipin III in fresh serum-free medium for 3 h at
37 °C. After further incubation for 22 h in the presence of 1 ml FBS-supplemented
medium per well (without inhibitors) metabolic activity was determined using an
MTT/thiazolyl blue assay: the medium was reduced to 500 µl per well and 25 µl of a
5 mg/ml solution of MTT in PBS was added to each well. After incubation for 1-2 h at
37 °C, the medium was removed, 250 µl DMSO was added and the plate was
incubated for 30 min at 37 °C under constant shaking. Absorbance was measured at
590 nm (reference wavelength 630 nm) using a microplate reader (Spectrafluor Plus,
Tecan Austria GmbH, Grödig, Austria) and cell viability was expressed as percentage
relative to untreated control cells.
2.7 Western blot
For western blot analysis, cells were seeded in 12 well plates at a density of 8 x 104
cells per well 24 h prior to the experiment. Polyplexes containing 6 µg of DNA
(pCMVLuc) and free mEGF at a concentration equivalent to the amount of mEGF
incorporated into the mEGF(+) complexes (20 pmol) were added to the cells in 1 ml
fresh culture medium. After the indicated time, cells were washed once with ice-cold
PBS and collected in 250 µl of homogenizing buffer (50 mM Tris/HCl, pH 7.4,
250 mM mannitol, 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol, 1 % (v/v) TritonX-
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100, protease inhibitor cocktail tablets (Roche), and phosphatase inhibitors mixtures I
and II (Sigma)) . Lysed cells were then centrifuged at 15,000•g for 15 min at 4 °C,
and the protein content in the supernatant was determined using the Pierce BCA kit
(Perbio Science, Bonn, Germany). For immunoblot analysis, 40 µg of solubilized
protein were separated by electrophoresis in a polyacrylamide gel and transferred to
a polyvinylidene fluoride (PVDF) sheet. The PVDF membrane was incubated for 1 h
in 5 % non-fat milk at room temperature and immunoreacted overnight at 4 °C with
monoclonal anti-phospho-Akt (New England Biolabs, Beverly, MA, USA), polyclonal
anti-Akt (New England Biolabs), monoclonal anti-extracellular-signal-regulated kinase
(Erk) 1,2 (New England Biolabs), polyclonal anti-phospho-Erk 1,2 (New England
Biolabs) or monoclonal anti-phospho-EGFR (New England Biolabs) antibodies
(0.1 mg/ml, 1:1000). The membrane was then processed using horseradish
peroxidase-conjugated secondary anti-rabbit antibodies (VectorLabs, Burlingame,
CA, USA) (1:2000) followed by a chemiluminescence detection method (ECL,
Amersham, Arlington Heights, IL, USA). Electrophoresis and immunoblotting were
performed in cooperation with Stefan Landshamer.
2.8 Cell synchronization
Cells were synchronized at G1 phase by a standard thymidine blocking procedure
(110). Strategy (i): Cells were cultured in complete medium containing 20 mM
thymidine for 16 h. After medium change, cells were further cultured in the presence
of 25 mM thymidine to keep the number of mitotic cells low (“continuous thymidine
block”). Strategy (ii): Cells were cultured in complete medium containing 5 mM
thymidine for 16 h. After medium change, cells were further cultured in the absence
of thymidine to allow cell cycle progression of synchronized cells (“thymidine
release”).
For analysis of cell cycle phases at different time points, cells were fixed as follows:
Approximately 105 cells including cell supernatants were harvested, centrifuged and
resuspended in 0.2 ml PBS. The cell suspension was then added dropwise to 2 ml of
ice-cold 80 % ethanol and kept at - 20 °C (at least overnight). Cells were stained by
incubation with 50 µg/ml PI, 0.005 % Triton X-100 and 10 µg/ml RNase A (Qiagen)
for 60 min at 37 °C and analyzed using a CyanTM MLE flow cytometer (Dako,
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Copenhagen, Denmark). PI fluorescence was excited at 488 nm and emission was
detected using a 613/20 nm bandpass filter. Data acquisition and analysis were
performed in linear mode. To discriminate between viable and dead cells and to
exclude doublets, cells were appropriately gated by forward/side scatter and pulse
width.
Data analysis was carried out using Summit (Summit v3.3, Dako) and `WinMDI´
(http://facs.scripps.edu/software.html). Cell cycle distribution was analyzed using
`Cylchred´ software (http://www.cardiff.ac.uk/index.html).
2.9 Luciferase reporter gene expression
2.9.1 Luciferase reporter gene expression
Cells were seeded in 96 well plates at a density of 104 cells per well 24 h prior to
transfection. Transfection complexes with indicated amounts of DNA (pCMVLuc)
were added to the cells in 100 µl fresh culture medium. Medium was replaced 4 h
after transfection and gene expression was measured after further 20 h. Detection of
luciferase activity was carried out as described recently (65). Transfection efficiency
was expressed as relative light units (RLU) per seeded cells.
2.9.2 Luciferase reporter gene expression after cell synchronization
Cells were seeded in 24 well plates at a density of 4 x 104 cells per well 24 h prior to
thymidine treatment. Cells were cultured in complete medium containing 20 mM
thymidine for 16 h followed by a medium change with 25 mM thymidine (“continuous
thymidine block”). Subsequently, transfection complexes were added to the cells.
Medium was replaced 4 h after transfection and gene expression was measured after
further incubation for 14 h. Detection of luciferase activity was carried out as
described in 2.9.1.
Cells were seeded in 24 well plates at a density of 2.5 x 104 cells per well 24 h prior
to thymidine treatment. Cells were cultured in complete medium containing 5 mM
thymidine for 16 h. After medium change, cells were further cultured in the absence
of thymidine to allow cell cycle progression of synchronized cells (“thymidine
release”). 4 h after thymidine removal, transfection complexes were added to the
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cells. Medium was replaced 4 h after transfection and gene expression was
measured at the indicated time points. Detection of luciferase activity was carried out
as described in 2.9.1.
2.9.3 Luciferase reporter gene expression in the presence of endocytosis
inhibitors
Cells were seeded in 24 well plates at a density of 5 x 104 (HUH-7) or 3 x 104 (HeLa)
cells per well 24 h prior to the experiment. Cells were preincubated with
chlorpromazine or filipin III in fresh serum-free medium for 1 h. Subsequently,
transfection complexes were added and incubation was continued for 2 h before
replacing with FBS-supplemented medium without inhibitor. After further incubation
for 22 h, luciferase activity was determined as described in 2.9.1. Where indicated,
luciferase activity was normalized for protein content (Pierce BCA protein assay,
Pierce, Rockford, Illinois) using BSA as a standard.
2.9.4 Luciferase reporter gene expression of HUH-7 EGFP-Luc cells
HUH-7 cells stably expressing EGFP-Luc (see 2.14) were seeded in 24 well plates at
a density of 5 x 104 cells per well 24 h prior to the experiment.
Cells were treated with different concentrations of chlorpromazine or filipin III in fresh
serum-free medium for 3 h at 37 °C. After further incubation for 22 h in the presence
of FBS-supplemented medium (without inhibitors), luciferase activity was determined
as described in 2.9.1.
Cells were cultured in complete medium containing 20 mM thymidine for 16 h
followed by a medium change with 25 mM thymidine (“continuous thymidine block”).
Gene expression was measured after further incubation for 22 h. Detection of
luciferase activity was carried out as described in 2.9.1.
2.10 EGFP reporter gene expression
2.10.1 EGFP reporter gene expression
Cells were seeded in 12 well plates at a density of 8 x 104 cells per well 24 h prior to
transfection. Transfection complexes with indicated amounts of DNA (pEGFP-N1)
were added to the cells in 1 ml fresh culture medium. Medium was replaced 4 h after
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transfection. Cells were harvested 48 h posttransfection by treatment with
trypsin/EDTA solution and kept on ice until analysis. The percentage of transfected
cells was determined using a CyanTM MLE flow cytometer (Dako). EGFP
fluorescence was excited at 488 nm and emission was detected using a 530/40 nm
bandpass filter and a 575/25 nm bandpass filter to analyze EGFP-positive cells by
diagonal gating (17). To discriminate between viable and dead cells and to exclude
doublets, cells were appropriately gated by forward/side scatter and pulse width, and
2 x 104 gated events per sample were collected.
2.10.2 EGFP reporter gene expression after cell synchronization
Cells were seeded in 12 well plates at a density of 8 x 104 cells per well 24 h prior to
thymidine treatment. Cells were cultured in complete medium containing 20 mM
thymidine for 16 h followed by a medium change with 25 mM thymidine (“continuous
thymidine block”). Subsequently, transfection complexes were added to the cells.
Medium was replaced 4 h after transfection and cells including cell supernatants
were harvested after further incubation for 18 h by treatment with trypsin/EDTA
solution. The percentage of transfected cells was determined as described in 2.10.1.
Cells were seeded in 12 well plates at a density of 5 x 104 cells per well 24 h prior to
thymidine treatment. Cells were cultured in complete medium containing 5 mM
thymidine for 16 h. After medium change, cells were further cultured in the absence
of thymidine to allow cell cycle progression of synchronized cells (“thymidine
release”). 4 h after thymidine removal, transfection complexes were added to the
cells. Medium was replaced 4 h after transfection and cells including cell
supernatants were harvested after the indicated time points by treatment with
trypsin/EDTA solution. The percentage of transfected cells was determined as
described in 2.10.1.
2.11 Flow cytometry
2.11.1 Correlation of cell association, EGFP expression and cell cycle phase
Cells were seeded in 6 well plates at a density of 2 x 105 cells per well 24 h prior to
transfection. Polyplexes containing Cy5-labeled DNA (20 % Cy5-DNA) were added to
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the cells at a DNA concentration of 10 µg/ml and cells were harvested after 6 h
incubation at 37 °C by treatment with trypsin/EDTA solution. Cells were washed with
PBS and stained with 5 µg/ml Hoechst 33342 for 30 min at 37 °C. Cells were then
assayed using a CyanTM MLE flow cytometer (Dako) equipped with a water-cooled
Enterprise II laser (model 621, Coherent) delivering light at 364 nm and 488 nm and
a laser diode with emission at 635 nm. Hoechst 33342 was excited at 364 nm and
emission was detected at 450/50 nm. The fluorophore Cy5 was excited at 635 nm
and emission was detected at 665/20 nm. Flow cytometric analysis was performed
as described in 2.10.1.
2.11.2 Analysis of cell surface EGFR levels after transfection
Cells were seeded in 12 well plates at a density of 8 x 104 cells per well 24 h prior to
transfection. Polyplexes were added to the cells at a DNA concentration of 3 µg/ml in
1 ml of fresh culture medium. After 2 h, cells were detached using 5 mM EDTA in
PBS. Cells were washed with PBS, resuspended in 0.1 % BSA and incubated with
mouse anti-huEGFR antibody (1:500) (clone H11, M3563, Dako, Hamburg,
Germany) for 1 h at 4 °C. Control cells were incubated accordingly with IgG1 mouse
antibody (1:100) (X0931, Dako, Germany). After washing with 0.1 % BSA, samples
were stained with goat anti-mouse IgG1 antibody linked to Alexa Fluor® 350 (1:200)
(Molecular Probes) for 1 h at 4 °C. Shortly before acquisition, YOYO-1 was added at
a final concentration of 1 µM. EGFR levels were determined by flow cytometry. Alexa
Fluor® 350 was excited at 364 nm and emission was detected at 450/50 nm. To
discriminate between viable and dead cells, cells incorporating high levels of YOYO-
1 and showing a reduction in forward scatter as a measure for cell size were
excluded from further analysis. To exclude doublets, cells were appropriately gated
by forward scatter/pulse width. 2 x 104 gated events per sample were collected.
2.11.3 Analysis of cellular polyplex association
Cells were seeded in 12 well plates at a density of 8 x 104 cells per well 24 h prior to
transfection. Polyplexes containing Cy5-labeled DNA (20 % Cy5-DNA) were added to
the cells in 1 ml of fresh culture medium. Cells were harvested after 30 min, 2 h or
4 h incubation at 37 °C by treatment with trypsin/EDTA solution and kept on ice until
analysis. Cell association of polyplexes was assayed by flow cytometry. The
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fluorophore Cy5 was excited at 635 nm and emission was detected at 665/20 nm. To
discriminate between viable and dead cells and to exclude doublets, cells were
appropriately gated by forward/side scatter and pulse width, and 2 x 104 gated events
per sample were collected. Median channel values +/- SD of triplicates (representing
the median intensity of cell-associated DNA) were determined and presented as
relative fluorescence units (RFU) with the highest value defined as 100 %.
2.11.4 Analysis of cellular polyplex uptake
To assay the kinetics of cellular internalization, a procedure described by Ogris et al.
(111) was adopted and slightly modified. Cells were seeded in 12 well plates - coated
with collagen G (Biochrom AG, Berlin, Germany) - at a density of 8 x 104 cells per
well 24 h prior to transfection. Polyplexes containing Cy5-labeled DNA (20 % Cy5-
DNA) were added to the cells in fresh culture medium. Cells were harvested after
30 min, 2 h or 4 h incubation at 37 °C by treatment with 105 Units per ml collagenase
A solution (Biochrom). To remove extracellularly-bound PEI and EGF(-) complexes,
cells were first treated with 100 I.E. heparin for 30 min at 37 °C (in the presence of
75 mM sodium azide to inhibit endocytosis) and then harvested by treatment with
trypsin/EDTA solution. To remove extracellularly-bound mEGF(+) complexes, cells
were treated with HEPES buffer (20 mM HEPES, pH 7.1) containing 150 mM sodium
azide, 1000 I.E./ml heparin, 0.5 % (w/v) trypsin and 2.5 mM EDTA for 30 min at
37 °C. Cells were then harvested and centrifuged. To assure that all extracellularly-
bound polyplexes were removed, cells were stained on ice with YOYO-1 at a final
concentration of 1 µM. To allow correlation of Cy5 and YOYO-1 fluorescence signals,
control transfections were carried out for 1 h at 4 °C when endocytosis is inhibited
(with additional 40 mM sodium azide during incubation at 37 °C while harvesting).
Cellular polyplex uptake was assayed by flow cytometry. The fluorophores YOYO-1
and Cy5 were excited at 488 nm and 635 nm, respectively, and emission was
detected at 530/40 nm and 665/20 nm, respectively. To discriminate between viable
and dead cells, cells incorporating high levels of YOYO-1 and showing a reduction in
forward scatter as a measure for cell size were excluded from further analysis. To
exclude doublets, cells were appropriately gated by forward scatter/pulse width.
2 x 104 gated events per sample were collected.
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2.11.5 Analysis of cellular polyplex uptake in the presence of uptake inhibitors
Cells were seeded as described in 2.11.2. They were preincubated with
chlorpromazine or filipin III in fresh serum-free medium for 1 h. Subsequently,
polyplexes containing Cy5-labeled DNA (20 % Cy5-DNA) were added to the cells.
After 2 h, extracellularly-bound complexes were removed and cells were analyzed as
described in 2.11.3.
Flow cytometric data were analyzed using Summit (Summit v3.3, Dako) and
`WinMDI´ software (http://facs.scripps.edu/software.html).
2.12 Epifluorescence microscopy
2.12.1 Analysis of cellular polyplex association
Cells were seeded on medco glass slides (10 well, Medco, Munich, Germany) coated
with collagen G (Biochrom) at a density of 3 x 103 cells per well 24 h prior to
transfection. Cells were transfected with Cy3-labeled DNA complexes (4 % Cy3-
DNA) at a concentration of 250 ng DNA per well. After 2 h incubation at 37 °C, the
slides were washed twice with PBS, fixed with 4 % paraformaldehyde, permeabilized
with 0.1 % Triton X-100 and the nuclei were stained with DAPI. Afterwards, samples
were mounted with vectashield mounting medium (Vector Laboratories, Burlingame,
CA, USA) and covered with a coverslip. Samples were visualized on an Axiovert 200
fluorescence microscope (Carl Zeiss, Jena, Germany) equipped with a Zeiss
Axiocam camera. Light was collected through a 63 x 1.4 NA oil immersion objective
(Zeiss). Cy3 fluorescence was excited using a 546/12 nm bandpass filter and
emission was detected using a 575-640 nm bandpass filter (Zeiss Filter Set 20).
DAPI fluorescence was excited using a G 365 nm filter and emission was detected
using a 420 nm longpass (Zeiss Filter Set 02). Digital image recording and image
analysis were performed with the Axiovision 3.1 software (Zeiss).
2.12.2 Cellular uptake of transferrin and cholera toxin B
Cells were seeded in Lab-Tek 8 Chambered Coverglasses (Nalge Nunc
International, Naperville, IL, USA) at a density of 2 x 104 cells per chamber 24 h prior
to the experiment. Cells were treated with chlorpromazine or filipin III in fresh serum-
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free medium for 1 h at 37 °C. Subsequently, Alexa Fluor® 647 transferrin or Alexa
Fluor® 488 CTB were added at a concentration of 10 µg/ml or 5 nM, respectively.
After 30 min at 37 °C, medium was replaced. Living cells were visualized as
described in 2.12.1. Alexa Fluor® 647 fluorescence was excited using a 620/60 nm
bandpass filter and emission was detected using a 700/75 nm bandpass filter
(Chroma Technology Corp.). Alexa Fluor® 488 fluorescence was excited using a 450-
490 nm bandpass filter and emission was detected using a 515-565 nm bandpass
filter (Zeiss Filter Set 10).
2.13 Analysis of colocalization of polyplexes with transferrin or
CTB by confocal laser scanning microscopy
Cells were seeded in Lab-Tek 8 Chambered Coverglasses (Nalge Nunc) at a density
of 2 x 104 cells per chamber 24 h prior to transfection. Alexa Fluor® 647 transferrin
(10 µg/ml) and Cy3-labeled polyplexes (20 % Cy3-DNA) or Alexa Fluor® 488 CTB
(5 nM) and Cy5-labeled polyplexes (20 % Cy5-DNA) were added to the cells to allow
simultaneous internalization. Live cell imaging was performed 1-4 h after transfection
using a confocal laser scanning microscope (LSM 510, Zeiss) equipped with an
argon and two helium/neon lasers delivering light at 488, 543 and 633 nm,
respectively. Light was collected through a 100 x 1.4 NA oil immersion objective
(Zeiss). Cy3 fluorescence was excited with the 543 nm line; emission was collected
using a 565-615 nm bandpass filter. Excitation of Cy5 and Alexa Fluor® 647
fluorescence was achieved by using the 633 nm line with the resulting fluorescent
wavelengths observed with a 650 nm longpass filter. Alexa Fluor® 488 was excited
with the 488 nm line and emission was collected using a 500-550 nm bandpass filter.
No signal overspill between the individual fluorescence channels was observed. An
optical section thickness of 0.8 µm was chosen.
Digital image recording and image analysis were performed with the LSM 5 software
(version 3.0, Zeiss).
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2.14 Generation of stably transfected single cell clones
2.14.1 Plasmid DNA amplification and preparation
For amplification of plasmid DNA, competent cells of bacterial strain E. coli DH5α
(Invitrogen) were transformed with the plasmid DNA, the transformation mix was
plated onto a selection agar plate (kanamycin, 30 µg/ml) and incubated at 37 °C
overnight. A single bacterial colony was picked, inoculated into 1 ml of LB medium
containing kanamycin and incubated at 37 °C with vigorous shaking for 8 h. This
culture was then inoculated into 250 ml of LB medium containing the appropriate
antibiotic. After incubation at 37 °C overnight with shaking, the bacterial culture was
harvested by centrifugation and the plasmid DNA was isolated using the EndoFree
Plasmid Maxi Kit (Qiagen) according to the manufacturer´s instructions. The DNA
was resuspended in 150 µl of sterile destilled water and quantified by absorption at
260 nm.
2.14.2 Generation of stably expressing EGFP-Actin cells, EGFP-Tubulin cells
and EGFP-Luciferase cells
For the generation of stably expressing EGFP-Actin cells, EGFP-Tubulin cells or
EGFP-Luciferase cells, vectors were linearized wih the restriction enzymes ApaL I,
MlU I or Dra III, respectively. HUH-7 cells were transfected using LPEI polyplexes
generated in HBS ½ with an N/P ratio of 6. Cells were incubated in fresh medium for
48-72 h and then selected with 200 µg/ml (EGFP-Actin/-Tubulin) or 100 µg/ml
(EGFP-Luciferase) G418. After several days, surviving cells were seeded at low
densities into 6 well plates in order to obtain separate colonies. When the cells had
grown up, single cell clones were isolated and expanded. The generated clones were
analyzed for the percentage of EGFP-positive (EGFP-Actin, EGFP-Tubulin or EGFP-
Luciferase stably transfected) cells by flow cytometry. Single cell clones
characterized by a single population with all cells positive for EGFP were chosen and
expanded.
2.15 Statistical analysis
Where indicated, one-way analysis of variance (ANOVA) with subsequent Duncan
test was performed.
3 Results 38
3 Results
3.1 EGFR-targeting enhances transfection efficiency of
PEGylated PEI polyplexes
To elucidate the cellular mechanisms of EGFR-targeted gene delivery, transfection
characteristics of PEG-shielded EGF-containing PEI polyplexes (EGF(+) complexes)
were compared to those of PEG-shielded EGF-free polyplexes (EGF(-) complexes)
in EGFR-expressing cell lines.
3.1.1 EGFR-targeted and PEG-shielded polyplexes maintain their biophysical
properties upon freeze-thawing
For the formation of mEGF(+) polyplexes, LPEI, PEG-PEI25 and mEGF-PEG-PEI25
conjugates were diluted in HEPES-buffered glucose (HBG) and then mixed with
plasmid DNA at a ratio of PEI nitrogen to DNA phosphate (N/P ratio) of 6. This gave
rise to small-sized particles displaying a nearly neutral surface charge owing to the
shielding coat of 20 kDa PEG. The EGF ligand attached to the distal end of a 3.4 kDa
PEG chain was supposed to show good accessibility to its receptor. These
polyplexes were compared to EGF-free particles containing the same amount of PEG
shield (EGF(-) complexes). Targeted and non-targeted complexes did not differ in
particle size (approximately 140 nm in diameter) and zeta potential (approximately
+ 2.5 mV) (Table 2).
PEGylated PEI polyplexes generated in HBG have been shown to maintain their
biophysical properties upon freeze-thawing (107). This was found to be important for
the retention of transfection rates (17). Therefore, after incubation for 30 min at room
temperature, polyplexes were snap-frozen in liquid nitrogen and stored at - 80 °C.
After thawing, biophysical properties of both formulations were comparable to those
of the corresponding fresh complex (Table 2).
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polyplex before freezing after thawing
EGF(-) 119 (+/- 11) 116 (+/- 11)
mEGF(+) 146 (+/- 8) 156 (+/- 14)
polyplex before freezing after thawing
EGF(-) 2.3 (+/- 0.2) 2.3 (+/- 0.1)
mEGF(+) 2.7 (+/- 0.6) 2.6 (+/- 0.8)
particle size (nm)
zeta potential (mV)
Table 2: Biophysical properties of EGF(-) and mEGF(+) polyplexes before and after the
freezing/thawing procedure.
3.1.2 EGFR-targeting increases transgene expression mediated by
PEGylated PEI polyplexes
To evaluate the capacity of EGFR-targeted polyplexes to improve gene transfer into
EGFR-expressing cells, transfection efficiency was assayed and compared to that of
EGF(-) complexes. Therefore, luciferase activity was analyzed in two different tumor
cell lines (HUH-7 and Renca-EGFR) after transfection with increasing amounts of
DNA.
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Figure 4: Reporter gene expression (luciferase activity) after transfection with EGF(-) and mEGF(+)
polyplexes. HUH-7 (A) and Renca-EGFR (B) cells were transfected with increasing amounts of DNA.
Luciferase activity was assayed 24 h after transfection and is presented as mean values + SD of
triplicates. ***p < 0.001; **p < 0.01; *p < 0.05, compared to EGF(-) complexes at the same DNA
concentration (ANOVA, Duncan).
In HUH-7, a human hepatocellular carcinoma cell line overexpressing the EGFR,
mEGF(+) complexes mediated a strong increase in luciferase activity at all DNA
concentrations tested (Figure 4A). They were found to be up to 50-fold more efficient
than EGF(-) complexes. In Renca-EGFR, a cell line stably expressing a plasmid
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encoding EGFR, luciferase activity was enhanced up to 12-fold at DNA
concentrations above 500 ng/ml, whereas at very low concentrations no targeting
effect could be detected (Figure 4B).
To evaluate whether the EGFR was involved in EGFR-mediated gene transfer, a
competition assay was performed. Transfection was carried out in the presence of a
1000-fold molar excess of free mEGF. The same amount of BSA was added to
control cells.
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Figure 5: Reporter gene expression (luciferase activity) with competitive inhibition of EGFR-
mediated gene transfer. HUH-7 cells were transfected with EGF(-) and mEGF(+) polyplexes at a DNA
concentration of 2.5 µg/ml. Cells were coincubated with a 1000-fold molar excess of free competing
ligand (mEGF). Control cells were transfected in the presence of BSA. Luciferase activity was assayed
24 h after transfection and is presented as mean values + SD of triplicates. ***p < 0.001; **p < 0.01;
*p < 0.05, compared to cells with BSA treatment (ANOVA, Duncan).
Competition of free EGF with EGF-containing polyplexes resulted in a decrease in
transfection efficiency down to the levels of EGF(-) complexes (Figure 5). In contrast,
addition of BSA – a protein which does not interact with the EGFR – did not reduce
EGFR-mediated gene transfer. Notably, luciferase activity of EGF(-) complexes
increased when free EGF was added. This might be due to the fact that EGF is
capable of triggering mitotic signaling leading to a higher percentage of dividing cells.
This favors nuclear entry during nuclear disassembly. However, despite the high
concentration of free EGF, luciferase activity did not reach the levels mediated by
mEGF(+) complexes, indicating that EGFR activation, if at all involved, is not the
major reason for enhanced transfection efficiency of targeted polyplexes.
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3.1.3 mEGF can substitute huEGF in the synthesis of EGFR-targeted PEI
polyplexes
EGF proteins are evolutionary closely conserved. For example, human and murine
EGF have 37 amino acids in common. Since murine EGF (mEGF, Kd = 10
-6 - 10-10 M
(112)) displays a binding activity towards the human EGFR similar to human EGF
(huEGF, Kd = 10-9 - 10-10 M (94)), it can be used to substitute huEGF in the synthesis
of gene delivery carriers. For this purpose, mEGF is even favored over huEGF
because it contains only one amino group at the N-terminus whereas huEGF
contains two lysines in the peptide chain (Lys 28 and Lys 48) bearing further reactive
amino groups which hampers specific chemical coupling via amino functions
(113;114).
Experiments described above (3.1.1 and 3.1.2) were performed with poyplexes
carrying murine EGF as the ligand for EGFR-specific gene delivery. In order to
validate this model, a huEGF-PEG-PEI25 conjugate was evaluated for transfection
efficiency where huEGF was selectively coupled to PEG via its N-terminal amino
group. N-terminal site-specific PEGylation was achieved by modification of huEGF at
a slightly acidic pH to enable selective deprotonation of the α-amino group (114).
huEGF(+) polyplexes were generated with amounts of EGF and PEG equivalent to
that of mEGF(+) polyplexes and analyzed in terms of luciferase reporter gene
expression in HUH-7 cells.
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Figure 6: Reporter gene expression (luciferase activity) after transfection with EGF(-), mEGF(+)
and huEGF(+) polyplexes. HUH-7 cells were transfected with increasing amounts of DNA. Luciferase
activity was assayed 24 h after transfection and is presented as mean values + SD of triplicates.
Transfection data of huEGF(+) polyplexes were analyzed for statistical significance. ***p < 0.001;
**p < 0.01; *p < 0.05, compared to EGF(-) complexes at the same DNA concentration (ANOVA,
Duncan).
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It was found that gene transfer efficiency of huEGF(+) polyplexes was only slightly
higher than that of the corresponding mEGF(+) complexes (Figure 6). This indicates
that mEGF is able to substitute huEGF in the design of EGFR-targeted gene delivery
vehicles.
In order to assess receptor specificity of EGFR-targeted gene transfer, free huEGF at
a 1000-fold molar excess was added to the culture medium during transfection.
Control cells were transfected in the presence of BSA at a protein concentration
equivalent to the amount of free huEGF.
1E+2
1E+3
1E+4
1E+5
EGF(-) huEGF(+)
R
L
U
/1
0.
00
0
ce
lls
control
with BSA
with huEGF
Figure 7: Reporter gene expression (luciferase activity) with competitive inhibition of EGFR-
mediated gene transfer. HUH-7 cells were transfected with EGF(-) and huEGF(+) polyplexes at a DNA
concentration of 1.25 µg/ml. Cells were coincubated with a 1000-fold molar excess of free competing
ligand (huEGF). Control cells were transfected in the presence of BSA. Luciferase activity was
assayed 24 h after transfection and is presented as mean values + SD of triplicates. ***p < 0.001;
**p < 0.01; *p < 0.05, compared to cells with BSA treatment (ANOVA, Duncan).
A pattern similar to that with mEGF(+) complexes (Figure 5) was observed:
transfection efficiency of huEGF(+) polyplexes was reduced in the presence of free
competing ligand, however not significantly. In contrast, exogeneous EGF enhanced
gene transfer by EGF(-) complexes (Figure 7), probably due to the mitogenic activity
of the free growth factor. Surprisingly, non-targeted transfection in the presence of
free huEGF yielded higher efficiencies than EGFR-targeted gene delivery under the
same conditions. This suggested that in this experiment, further important factors
played a role which, however, could not be identified.
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3.1.4 EGFR-targeting increases the number of cells transfected by PEGylated
PEI polyplexes
In order to test whether enhanced gene transfer efficiency by EGFR-targeted
polyplexes was associated with an increase in the number of transfected cells, the
percentage of transfected cells was analyzed. HUH-7 and Renca-EGFR cells were
transfected using Enhanced Green Fluorescent Protein (EGFP)-encoding DNA
complexes and EGFP expression was determined 48 h posttransfection. In line with
the results obtained in the luciferase assay (Figure 4), EGF-containing polyplexes
showed a strong increase in transfection efficiency. With EGF(-) complexes, the
percentage of transfected cells was very low (0.4 %) in HUH-7 and moderate (11 %)
in Renca-EGFR. With mEGF(+) complexes, however, up to 13 % (HUH-7) and 20 %
(Renca-EGFR) expressed EGFP. This corresponds to a 29-fold and 2-fold increase,
respectively (Figure 8).
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Figure 8: Reporter gene expression (EGFP expression) after transfection with EGF(-) and
mEGF(+) polyplexes. HUH-7 (A) and Renca-EGFR (B) cells were transfected with the indicated
amounts of DNA. The percentage of EGFP-positive cells was analyzed by flow cytometry 48 h after
transfection and is presented as mean values + SD of triplicates. ***p < 0.001; **p < 0.01; *p < 0.05,
compared to EGF(-) polyplexes at the same DNA concentration (ANOVA, Duncan).
To test whether this increase in transfection efficiency was mediated by a specific
interaction between the EGFR and its ligand, transfection was carried out in the
presence of a 1000-fold molar excess of free competing ligand or BSA as irrelevant
control.
Figure 9 illustrates that gene transfer efficiency of EGF(-) complexes in the presence
of free mEGF did not change, whereas EGFR-mediated transfection was reduced to
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nearly the levels found for the receptor-independent transfection when free mEGF
was added. Notably, transfection efficiency of EGF(-) complexes was not enhanced
in the presence of free mEGF, as it had been observed in the luciferase assay
(Figure 5, Figure 7).
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Figure 9: Reporter gene expression (EGFP expression) with competitive inhibition of EGFR-
mediated gene transfer. HUH-7 cells were transfected with EGF(-) and mEGF(+) polyplexes at a DNA
concentration of 0.63 µg/ml. Cells were coincubated with a 1000-fold molar excess of free competing
ligand (mEGF). Control cells were transfected in the presence of BSA. The percentage of EGFP-
positive cells was analyzed by flow cytometry 48 h after transfection and is presented as mean values
+ SD of triplicates. ***p < 0.001; **p < 0.01; *p < 0.05, compared to cells with BSA treatment (ANOVA,
Duncan).
To further confirm that the EGFR was essential for improved transfection efficiency of
EGFR-targeted polyplexes, EGFR-free Renca-LacZ cells were transfected with
EGF(-) and mEGF(+) complexes.
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Figure 10: Reporter gene expression (EGFP expression) after transfection with EGF(-) and
mEGF(+) polyplexes. Renca-LacZ cells were transfected with the indicated amounts of DNA. The
percentage of EGFP-positive cells was analyzed by flow cytometry 48 h after transfection and is
presented as mean values + SD of triplicates.
No difference between transfection efficiency of targeted and non-targeted
polyplexes could be detected, indicating that EGF(+) complexes do not enhance
gene transfer into EGFR-free cells (Figure 10). Accordingly, transfection of Renca-
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LacZ cells with mEGF(+) complexes could not be reduced by coincubation with free
mEGF (data not shown).
In summary, EGFR-targeted PEI polyplexes (mEGF(+)) mediated enhanced gene
transfer into both HUH-7 and Renca-EGFR cells compared to non-targeted, shielded
(EGF(-)) complexes. Overall transgene expression as well as the number of
transfected cells increased after transfection with complexes containing murine EGF.
Transfection efficiency of mEGF(+) polyplexes was comparable to that of huEGF(+)
complexes, indicating that human EGF can be substituted by murine EGF in the
synthesis of EGFR-targeted gene delivery vectors. Furthermore, receptor specificity
of EGFR-targeted transfection was suggested by the observation that addition of free
EGF as competing ligand reduced transfection efficiency close to the level of non-
targeted transfection. This finding suggests that free mEGF acts by interference with
EGFR-mediated cellular polyplex binding and internalization. Therefore, cellular
uptake characteristics of mEGF(+) polyplexes were analyzed next.
3.2 EGFR-targeting improves cellular uptake of PEGylated PEI
polyplexes
Cellular uptake processes of PEI polyplexes can be divided into two steps: First, the
particle attaches to the cell membrane due to receptor-ligand interactions or
electrostatic attraction, and second, the particle gets internalized, usually by
subsequent formation of small vesicles. Both steps might be enhanced by
incorporation of a ligand into the polyplex.
3.2.1 EGFR-targeting improves total cellular association of PEGylated PEI
polyplexes
To determine whether enhanced cellular binding contributed to the increased
transfection efficiencies of mEGF(+) complexes, cellular association studies were
performed using both HUH-7 and Renca-EGFR cells. EGF(-) and mEGF(+)
polyplexes were generated with Cy5-labeled DNA to enable analysis of cell-
associated particles by flow cytometry.
First, to determine how much complex attached to the exterior cell membrane, the
assay was performed by incubation at low temperatures when endocytosis is
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inhibited. Cells were incubated with polyplexes on ice and median Cy5 fluorescence
was determined 1 h posttransfection. Incubation with EGFR-targeted complexes
resulted in a more than six-fold increase in cellular association compared to EGF(-)
polyplexes which was only due to enhanced binding of particles to the cell surface,
because uptake processes were inhibited (data not shown).
Second, total cellular association was analyzed representing the amount of
extracellularly-bound and internalized complexes. Cells were transfected and total
cellular association of particles was analyzed after 30 min, 2 h and 4 h at 37 °C.
Median values of Cy5 fluorescence were determined and converted into relative
fluorescence units (RFU), with the highest value defined as 100 %.
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Figure 11: Total cellular associat ion of EGF(-) and mEGF(+) polyplexes. HUH-7 (A) and Renca-
EGFR (B) cells were transfected with complexes containing Cy5-labeled DNA at a DNA concentration
of 0.63 µg/ml. Cellular association was analyzed by flow cytometry after 30 min, 2 h and 4 h. Median
channel values were determined and presented as relative fluorescence units (RFU), with the highest
value defined as 100 %. Mean values +/- SD of triplicates are presented. ***p < 0.001; **p < 0.01;
*p < 0.05, compared to EGF(-) polyplexes at the same time point (ANOVA, Duncan).
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Incubation with mEGF(+) complexes resulted in strong cellular association which was
2- to 10-fold higher compared to EGF(-) complexes (Figure 11). The difference in
cellular association was already pronounced after only 30 min of incubation,
indicating a fast interaction of mEGF(+) polyplexes with the membrane of EGFR-
expressing cells.
Therefore, to evaluate involvement of the EGFR in this process, the assay was
carried out in the presence of free mEGF as competing ligand (1000-fold molar
excess) or BSA as irrelevant control. In contrast to the control cells incubated with
BSA, competition of free ligand with EGF-containing polyplexes reduced total cellular
association to nearly the same values found with non-targeted complexes (Figure
12). In contrast, receptor-independent cell association of EGF(-) complexes was not
affected by free EGF.
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Figure 12: Total cellular association of EGF(-) and mEGF(+) polyplexes with competitive inhibition of
EGFR/ligand interaction. HUH-7 (A) and Renca-EGFR (B) cells were transfected with complexes
containing Cy5-labeled DNA at a DNA concentration of 0.63 µg/ml. Cells were coincubated with a
1000-fold molar excess of free competing ligand (mEGF). Control cells were transfected in the
presence of BSA. Cellular association was analyzed by flow cytometry after 4 h. Median channel
values were determined and presented as relative fluorescence units (RFU), with the highest value
defined as 100 %. Mean values + SD of triplicates are presented. ***p < 0.001; **p < 0.01; *p < 0.05,
compared to cells with BSA treatment (ANOVA, Duncan).
To confirm EGFR specificity of cellular mEGF(+) polyplex binding, transfection was
performed in EGFR-free Renca-LacZ cells. As expected, no relevant differences in
total cellular association between targeted and non-targeted polyplexes could be
detected (Figure 13).
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Figure 13: Total cellular association of EGF(-) and mEGF(+) polyplexes. Renca-LacZ cells were
transfected with complexes containing Cy5-labeled DNA at a DNA concentration of 1.25 µg/ml.
Cellular association was analyzed by flow cytometry after 30 min, 2 h and 4 h. Median channel values
were determined and presented as relative fluorescence units (RFU), with the highest value defined
as 100 %. Mean values +/- SD of triplicates are presented.
Furthermore, huEGF(+) complexes were compared to EGF(-) and mEGF(+)
complexes in terms of total cellular association. huEGF(+) polyplexes attached to
HUH-7 cells just as well as mEGF(+) complexes, with fluorescence signals 2.5- to
3.5-fold higher than those of EGF(-) complexes (Figure 14).
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Figure 14: Total cellular association of EGF(-) and huEGF(+) polyplexes. HUH-7 cells were
transfected with complexes containing Cy5-labeled DNA at a DNA concentration of 1.25 µg/ml.
Cellular association was analyzed by flow cytometry after 30 min, 2 h and 4 h. Cellular association of
mEGF(+) polyplexes at the same DNA concentration served as a standard. Median channel values
were determined and presented as relative fluorescence units (RFU), with the highest value defined
as 100 %. Mean values +/- SD of triplicates are presented. ***p < 0.001; **p < 0.01; *p < 0.05,
compared to EGF(-) polyplexes at the same time point (ANOVA, Duncan).
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3.2.2 EGFR-targeted complexes cluster upon cell binding
To further characterize cellular association of polyplexes, HUH-7 cells were
transfected with complexes containing Cy3-labeled DNA and visualized by
fluorescence microscopy. Increased cell binding of mEGF(+) polyplexes was
associated with clustering of complexes bound to the cells. While EGF(-) polyplexes
appeared as a faint punctual pattern on the cells (Figure 15A), mEGF+ polyplexes
were observed as large aggregates of micrometer size (Figure 15B).
Figure 15: Clustering of mEGF(+) polyplexes upon cell binding. HUH-7 (A, B), Renca-EGFR (C) and
RencaLacZ (D) cells were incubated with Cy3-labeled EGF(-) (A) and mEGF(+) (B, C, D) polyplexes.
After 2h, cells were washed, fixed and counterstained with DAPI to visualize cell nuclei. Samples were
visualized by epifluorescence microscopy. Blue: DAPI-stained nuclei. Red: Cy3-labeled polyplexes.
Since both mEGF(+) and EGF(-) polyplexes had a similar particle size prior to
transfection, it was assumed that this effect relied on the interaction of polyplex-
bound EGF with the EGFR. Notably, when incubating mEGF(+) polyplexes with
(EGFR-positive) Renca-EGFR cells or (EGFR-negative) Renca-LacZ cells, only
Renca-EGFR cells mediated clustering of mEGF(+) polyplexes (Figure 15C, D).
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3.2.3 Internalization of EGFR-targeted complexes proceeds very fast
Total cellular association data did not provide any information about polyplex
internalization. Since receptor-mediated endocytosis is known to be a fast process
(115), it was assumed that uptake of receptor-targeted polyplexes proceeds much
faster than that of non-targeted complexes. To differentiate between extracellular and
intracellular polyplexes, cells were incubated with heparin which is able to remove
extracellularly-bound particles. The remaining Cy5 fluorescence then represented
only internalized particles. The absence of extracellularly-bound particles was verified
by subsequent addition of YOYO-1, a membrane impermeable DNA stain.
The kinetics of internalization of mEGF(+) polyplexes were analyzed using HUH-7
cells and compared to shielded (EGF(-)) and unshielded (LPEI) complexes. LPEI
polyplexes were generated in HBG at N/P 6 and had a size similar to that of EGF(-)
and mEGF(+) complexes (approximately 100 nm) but displayed a positive surface
charge (approximately + 20-30 mV). They were therefore used here to compare their
cellular binding/uptake properties to that of neutrally charged EGFR-targeted
polyplexes.
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Figure 16: Total cellular association and internalization after transfection with polyplexes. HUH-7
cells were transfected with mEGF(+) (A), EGF(-) (B) and LPEI complexes (HBG, N/P 6) (C) containing
Cy5-labeled DNA at a DNA concentration of 3 µg/ml. Internalization and total cellular association were
analyzed by flow cytometry after 30 min, 2 h and 4 h. Black: control. Red: 30 min. Green: 2 h.
Blue: 4 h.
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Figure 17: Cellular internalization of LPEI (HBG, N/P 6), EGF(-) and mEGF(+) polyplexes. Data are
derived from the results presented in Figure 16. (A) Percentage of cells containing polyplexes.
(B) Cellular uptake of polyplexes. Total cellular association of mEGF(+) polyplexes (after 4 h) was
defined as 100 %. Mean values +/- SD of duplicates are shown.
Uptake of EGFR-targeted polyplexes was very fast. Already 30 min after transfection,
approximately 81 % of the cells had taken up a significant amount of mEGF(+)
complexes (Figure 16 A, Figure 17A). After 2 h and 4 h, approximately 89 % and
93 % of the cells had internalized mEGF(+) complexes, respectively. In contrast,
binding and uptake of EGF(-) polyplexes was very slow with only approximately 5 %
of cells containing complexes 30 min posttransfection. Significant internalization,
however, could not be detected until 2 h (approximately 62 % Cy5-positive cells)
(Figure 16 B, Figure 17A). LPEI polyplexes – due to their strong positive zeta
potential – attached to the cells very fast (Figure 16 C) but uptake was obviously
slow: approximately 11 % and 77 % of cells had taken up LPEI polyplexes after
30 min and 2 h, respectively (Figure 16 C, Figure 17A).
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A similar pattern was found regarding the mean cellular polyplex uptake (Figure
17B): EGFR-targeted complex internalization was much faster than that of non-
targeted polyplexes. However, uptake velocity of mEGF(+) complexes was not
constant over the 4 h time period but slowed down already shortly after transfection
(approximately 30 min posttransfection). Notably, 4 h posttransfection, the mean
cellular uptake level was similar to that of LPEI polyplexes (Figure 17B). In contrast,
internalization levels of EGF(-) complexes were low at all time points, with 3- to 13-
fold less uptake compared to mEGF(+) polyplexes.
3.2.4 Reporter gene expression of EGFR-targeted polyplexes can be detected
already 4 h posttransfection
Fast uptake of mEGF(+) complexes should lead to an early onset of luciferase
activity after transfection with luciferase-encoding DNA polyplexes. In order to
evaluate this, time course measurements were performed. Cells were transfected
and luciferase activity was determined after 4 h, 8 h, 12 h and 24 h.
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Figure 18: Reporter gene expression (luciferase activity) at different time points after transfection.
HUH-7 cells were transfected with EGF(-) and mEGF(+) polyplexes at a DNA concentration of
1.25 µg/ml and luciferase activity was determined 4 h, 8 h, 12 h and 24 h posttransfection.
Transfection efficiencies of EGF(-) polyplexes 4 h and 8 h posttransfection were not detectable (n. d.).
Mean values +/- SD of triplicates are shown. ***p < 0.001; **p < 0.01; *p < 0.05, compared to EGF(-)
polyplexes at the same time point (ANOVA, Duncan).
Using mEGF(+) complexes, luciferase expression could already be detected 4 h after
transfection, whereas no activity was found with EGF(-) complexes at that time point
(Figure 18). The difference in transfection efficiency between the two formulations
used was most pronounced during the first 12 h of transfection, when efficiency was
enhanced up to 250-fold with mEGF(+) polyplexes compared to EGF(-) polyplexes.
This difference became smaller with time, resulting in an approximately 65-fold
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enhancement 24 h after transfection. This result was in accordance with the
observation that mEGF(+) polyplexes were internalized within a few minutes,
whereas EGF(-) complexes needed at least 2 h for significant uptake (Figure 17).
In summary, both cellular binding and uptake were accelerated and enhanced when
using EGFR-targeted polyplexes compared to non-targeted complexes (EGF(-)).
Cellular association of mEGF(+) complexes was comparable to that of huEGF(+)
complexes and could be inhibited by addition of free mEGF as competing ligand.
Remarkably, increased cellular binding of the targeted complexes was associated
with clustering of the particles bound to the cell. As expected, the fast internalization
process of mEGF(+) complexes was accompanied by a very early onset of reporter
gene expression which was already detectable 4 h posttransfection.
All these cellular binding and uptake kinetics data suggested that EGFR-targeted
polyplexes were internalized by the cells via receptor-mediated endocytosis.
Therefore, the putative interaction between EGFR-targeted polyplexes and the
receptor was further evaluated.
3.3 EGFR-targeted complexes specifically bind to the EGFR
To further characterize the cellular mechanism of EGFR-targeted gene delivery,
direct involvement of the EGFR had to be proven. However, evidence for specific
EGFR binding of mEGF(+) complexes is not only a key issue in elucidating the
mechanism of EGFR-targeted gene delivery but also of pharmacological value since
EGFR activity controls a wide variety of biological responses.
3.3.1 EGFR-targeted transfection reduces the level of free surface EGFR
To confirm binding of mEGF(+) polyplexes to the EGFR, the level of free surface
receptors was analyzed after transfection using a competitive antibody against the
EGFR. HUH-7 cells were incubated with EGF(-) and mEGF(+) complexes for 2 h
before staining free surface EGFR with a primary anti-huEGFR antibody and a
secondary antibody labeled with Alexa Fluor® 350. Cellular binding of mEGF(+)
complexes clearly decreased receptor levels accessible to the antibody, whereas that
of EGF(-) complexes did not (Figure 19).
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Figure 19: Level of free surface EGFR after transfection with polyplexes. HUH-7 cells were
transfected with EGF(-) and mEGF(+) complexes for 2 h at a DNA concentration of 3 µg/ml before
staining free surface EGFR with mouse anti-huEGFR antibody and goat anti-mouse IgG1 antibody
labeled with Alexa Fluor® 350. The median fluorescence intensity was determined by flow cytometry.
Two independent experiments were performed. Mean values + SD are presented.
3.3.2 EGFR-targeted polyplexes trigger EGFR activation
Receptor activation can serve as a strong indicator for a specific interaction between
complex-bound EGF and the EGFR. On the molecular level, ligand binding induces
dimerization of EGFRs and autophosphorylation in the cytoplasmic domain of EGFRs
(78). EGFR activation then initiates various signaling cascades involving PI3-
kinase/Akt and MAPK (Erk-1/2) signaling pathways (81;82;116). These are the most
prominent signaling pathways downstream EGFR activation mediating cell survival
and proliferation.
To assess whether EGFR binding by mEGF(+) polyplexes triggers these pathways,
western blot analysis was performed. Free mEGF equivalent to the amount of mEGF
incorporated into the mEGF(+) polyplex was used as a control.
Already 10 min after transfection, EGFRs were activated by EGF-containing
polyplexes (Figure 20). Receptors remained phosphorylated for approximately one
hour. Accordingly, the downstream signaling transducer Akt was also found to be
initiated after 10 min. Notably, phospho-Erk levels were already detectable under
control conditions, indicating constitutive Erk activity which was probably attributed to
the proliferating status of the tumor cells. mEGF(+) polyplexes then induced a
decrease of phospho-Erk levels below the level of untreated control cells.
3 Results 56
C
N
C
N
10
m
in
E
G
F
(-
),
30
m
in
30
m
in
1h 3h 6h 10
m
in
1h30
m
in
p-Akt
Akt
p-Erk
Erk
p-EGFR
mEGF(+) complexes mEGF
Figure 20: Activation of the EGFR and its downstream signaling transducer Akt by mEGF(+)
complexes. HUH-7 cells were treated with mEGF (20 pmol/ml = 120 ng/ml), mEGF(+) complexes or
EGF(-) polyplexes (DNA concentration 6 µg/ml). After the indicated time, western blot analysis of
phospho-EGFR, phospho-Akt and phospho-Erk-1/2 was performed. To confirm equal protein loading
in each lane, the levels of Akt and Erk-1/2 were analyzed. (CN: negative control)
Similar results were obtained with control cells treated with free mEGF alone (Figure
20). Increased levels of phospho-EGFR and phospho-Akt were detected within the
first 30 min after addition of the growth factor, whereas phospho-Erk levels
decreased. In contrast to mEGF(+) polyplexes, control complexes without EGF
(EGF(-)) did not induce EGFR activation and initiation of the downstream signaling
transducer Akt (Figure 20, right panel). This proved that the targeting ligand alone
was responsible for the EGFR activation observed with EGFR-targeted polyplexes.
This was also in line with (114) where it was reported that site-specific coupling of
EGF via its N-terminal amino group retained its biological activity.
In summary, incubation of EGFR-expressing cells with mEGF(+) polyplexes reduced
the amount of surface EGFR accessible to a competitive anti-huEGFR antibody,
indicating that mEGF(+) polyplexes might be able to occupy and/or downregulate
membrane EGFRs. Further evidence lies in the observation that EGFR-targeted
transfection was accompanied by activation of the receptor and its downstream
signaling transducer Akt. Ligand-induced and EGFR-mediated nuclear polyplex
accumulation was therefore considered to be another possible reason for enhanced
gene delivery with EGFR-targeted polyplexes. This would mean that EGFR-targeted
polyplexes are able to transfect postmitotic cells. Consequently, the cell cycle
dependency of EGFR-targeted gene delivery was further analyzed.
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3.4 EGFR-targeted gene delivery is cell cycle dependent
In the previous section (3.3.2), evidence for a specific interaction between cell
surface EGFR and complex-bound EGF was presented. Interestingly, it was recently
reported that the EGFR after stimulation with EGF is able to translocate to the
nucleus (92). Therefore, the possibility was considered that EGF mediates enhanced
nuclear accumulation of the polyplexes. For polyplex-mediated gene delivery, the
major path to nuclear entry seems to be via nuclear disassembly during mitosis (71).
If, however, EGF had a significant effect on nuclear import, this cell cycle
dependency should be less pronounced when using EGFR-targeted polyplexes. As a
prerequisite, EGFR expression levels were determined to be stable during cell cycle
progression (data not shown).
3.4.1 EGFR-targeted polyplexes transfect postmitotic cells inefficiently
To assess the role of mitosis in the process of EGFR-targeted transfection, gene
transfer experiments were carried out in a cell population which had been depleted of
mitotic cells.
To reduce the number of dividing cells, cell cycle progression was blocked at the
G1/S boundary by incubation with 20 mM thymidine (for 16 h). Notably, high dose
thymidine treatment is known to inhibit the ribonucleotide reductase which leads to
blockage of DNA replication at S phase. Thus, the percentage of cells in G2/M phase
decreased from 14 % (Figure 21: black) to 3.5 % (Figure 21: red). Since it was
intended to perform the transfection while keeping the number of mitotic cells low,
treatment was continued with 25 mM thymidine. As required, cell cycle distribution
remained similar with less than 5 % in G2/M phase after 34 h (Figure 21: blue).
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Figure 21: Cell cycle distribution after thymidine block. HUH-7 cells were incubated with 20 mM
thymidine for 16 h and further cultured in medium containing 25 mM thymidine. After the indicated
time, cells were fixed with ethanol and cell cycle distribution was assayed by flow cytometry using PI.
In order to evaluate the impact of mitosis on the transfection of EGFR-targeted and
non-targeted polyplexes, cell cycle progression was blocked as described above.
Transfection complexes coding for either luciferase or EGFP were then added at the
16 h time point (Figure 21: red). Since thymidine treatment was continued until
analysis (34 h time point, Figure 21: blue), the number of mitotic cells during
transfection remained low.
In this gene transfer experiment, mEGF(+) complexes were compared to both
shielded EGF(-) and unshielded LPEI polyplexes (HBS ½, N/P 6).
Transfection efficiency of both EGF(-) and mEGF(+) complexes decreased when the
number of mitotic cells was reduced by thymidine treatment. Transfection levels of
LPEI polyplexes were reduced five- and four-fold regarding luciferase activity and
EGFP expression rates, respectively (Figure 22). With EGF(-) complexes,
transfection decreased by a factor of six and nine, respectively (Figure 22). And with
mEGF(+) complexes, transfection efficiency was reduced four- and eight-fold,
respectively (Figure 22). Since transfection rates of EGFR-targeted complexes
decreased to an extent similar to that of non-targeted particles, these results
suggested that mEGF(+) polyplexes were not capable of transfecting postmitotic cells
efficiently. It was therefore assumed that EGF did not efficiently promote nuclear
import of PEI polyplexes.
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Figure 22: Reporter gene expression after transfection of cells synchronized at the G1/S boundary:
(A) EGFP expression and (B) Luciferase activity. HUH-7 cells were synchronized by a single
thymidine block (16 h) and transfected with LPEI (HBS ½, N/P 6), EGF(-) and mEGF(+) complexes in
the presence of thymidine (18 h). Control cells did not receive thymidine treatment. Luciferase activity
and the percentage of EGFP-expressing cells are presented as mean values + SD of duplicates.
It has to be taken into account, however, that reduced cell cycle progression also
decreases the cell number. Furthermore, thymidine might affect transgene
expression on the level of protein synthesis. Therefore, as a control, HUH-7 cells
stably expressing the luciferase gene were treated for the time of the complete
experiment (34 h) with the same amount of thymidine. In these cells, luciferase
activity was found to be 62.3 % (+/- 2.3 %) of untreated control cells (data not
shown). This result helped to estimate the impact of thymidine treatment on the level
of non-transient transgene expression.
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3.4.2 Mitosis has a major impact on EGFR-targeted gene delivery
To obtain further evidence for the role of mitosis in EGFR-targeted gene delivery,
transfection experiments were performed in synchronized but cycling cells. Hence, it
was expected that synchronized cells that pass mitosis simultaneously should show
a fast increase in transgene expression – provided that transfection is strongly cell
cycle dependent.
First, simultaneous cell cycle progression of synchronized cells was ensured: Cells
were synchronized by incubation with 5 mM thymidine for 16 h which was followed by
a medium cange to remove the thymidine. Cell cycle progression was then assayed
every 4 h.
Control
0 h after release
4 h after release
8 h after release
12 h after release
16 h after release
20 h after release
24 h after release
Figure 23: Cell cycle distribution after thymidine release. HUH-7 cells were incubated with 5 mM
thymidine for 16 h and further cultured in medium without thymidine. After the indicated time, cells
were fixed with ethanol and cell cycle distribution was assayed by flow cytometry using PI.
It revealed that after thymidine release, cells re-entered the cell cycle simultaneously
and were found to pass mitosis between 12 h and 20 h later (Figure 23).
In order to evaluate the impact of mitosis on transfection efficiency of EGFR-targeted
and non-targeted polyplexes, cells were synchronized as described above.
Transfection complexes coding for either luciferase or EGFP were then added 4 h
after thymidine removal. Consequently, cells passed mitosis simultaneously 8-16 h
posttransfection. It was expected that at this time, transgene expression should show
a fast increase – provided that transfection was strongly cell cycle dependent.
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Figure 24: Reporter gene expression after transfection of cells synchronized at the G1/S boundary.
HUH-7 cells were synchronized by a single thymidine block (16 h) and transfected with LPEI (HBS ½,
N/P 6), EGF(-) and mEGF(+) complexes in the absence of thymidine (4 h after thymidine release).
Control cells did not receive thymidine treatment. Luciferase activity (A, C) and the percentage of
EGFP-expressing cells (B, D) are presented as mean values +/- SD of duplicates. In (C, D), reporter
gene expression is presented as relative transfection efficiency, with the values at the 24 h time point
defined as 100 %.
16 h after release (i. e. 4 h after entering mitosis (see Figure 23)), reporter gene
expression was detectable (Figure 24). As illustrated by Figure 24 C and D,
progression in transgene expression mediated by targeted polyplexes was similar to
that mediated by non-targeted polyplexes. This suggests that nuclear disassembly
during mitosis is as important in EGFR-mediated transfection as it is in non-targeted
transfection.
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3.4.3 Mitosis amplifies efficiency of EGFR-targeted gene delivery
To further elucidate the cell cycle dependency of EGFR-targeted gene delivery,
EGFP reporter gene expression, cell cycle distribution and total cellular association
were monitored in parallel. Thus, 6 h posttransfection, flow cytometric analysis
should reveal correlations between these parameters. Notably, EGFR expression
levels had been determined to be stable during cell cycle progression (data not
shown). It was further ensured that gene transfer efficiency of labeled polyplexes was
not reduced compared to unlabeled particles (data not shown).
The CyanTM MLE flow cytometer used here was equipped with an enterprise II laser
delivering light at 364 nm and 488 nm and a laser diode with emission at 635 nm.
These three laser lines were applied to excite Hoechst 33342, EGFP and Cy5,
respectively. Sequential excitation of the three dyes minimized the risk of emission
crosstalk. Accordingly, no signal overspill between the three channels was observed
(data not shown). The use of Hoechst 33342 to quantify nuclear DNA was possible
due to the availability of a 364 nm excitation wavelength and enabled measurement
of living cells while avoiding fixative-induced artifacts. This was of high relevance
since many fixatives destroy plasma membrane integrity and thus cause leaking of
the fluorescent protein GFP (117;118).
Figure 25 illustrates the results after transfection with mEGF(+) complexes. Notably,
all three polyplex formulations showed similar results regarding these parameter
relations, irrespective the differences in EGFP expression and in the level of total
cellular polyplex association (Table 3).
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Figure 25: Correlation of EGFP expression, cell cycle phase and cellular polyplex association after
transfection with mEGF(+) polyplexes. HUH-7 cells were transfected with Cy5-labeled LPEI (HBS ½,
N/P 6), EGF(-) or mEGF(+) polyplexes coding for EGFP at a DNA concentration of 10 µg/ml. 6 h
posttransfection, cells were harvested, stained with Hoechst 33342 and analyzed by flow cytometry.
Data after transfection with LPEI or EGF(-) polyplexes are not shown. (Autofluo = Fl-2)
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cellular association
LPEI 3.1 (+/- 0.3) 26.5 (+/- 2.7) 174.7 (+/- 4.5)
EGF(-) 2.0 (+/- 0.1) 16.6 (+/- 0.0) 113.9 (+/- 14.5)
mEGF(+) 5.2 (+/- 0.4) 35.25 (+/- 1.8) 174.9 (+/- 13.3)
reporter gene expression
% EGFP-
positive cells
EGFP (median) of
EGFP-positive cells
Cy5 (median)
Table 3: Reporter gene expression (EGFP expression) and total cellular association 6 h after
transfection. Data are derived from the experiment illustrated by Figure 25. Mean values +/- SD of
duplicates are shown.
Admittedly, transgene expression was low in all samples, attributed to the short
transfection time of 6 h. A short incubation was, however, essential to draw
conclusions concerning the role of mitosis in this experiment. Accordingly,
identification of different cell populations allowed correlations between the
parameters cell cycle, reporter gene expression and cellular polyplex association.
LPEI 3.7 (+/- 0.3) % 1.4 (+/- 0.3) % 2,6 3.1 (+/- 0.3) %
EGF(-) 2.6 (+/- 0.2) % 0.7 (+/- 0.1) % 3,6 2.0 (+/- 0.1) %
mEGF(+) 6.8 (+/- 0.5) % 2.1 (+/- 0.5) % 3,2 5.2 (+/- 0.4) %
reporter gene expression (% GFP-expressing cells)
diploid cells tetraploid cells diploid/tetraploid total
Table 4: Correlation of transfection efficiency and cell cycle phase. Data are derived from the
experiment illustrated by Figure 25. “diploid cells” (or “tetraploid cells”) indicates the number of diploid
(or tetraploid) EGFP-positive cells related to the total number of diploid (or tetraploid) cells of each
sample. “total” is the total number of EGFP-positive cells related to the total number of cells of each
sample. “diploid/tetraploid” indicates the factor by which diploid cells were transfected more efficiently
than tetraploid cells (“diploid” divided by “tetraploid”). Mean values +/- SD of duplicates are shown.
To evaluate the role of mitosis in EGFR-targeted gene delivery, the number of diploid
(or tetraploid) EGFP-positive cells was related to the total number of diploid (or
tetraploid) cells of each sample. 6 h posttransfection, the fraction of diploid cells was
expected to be enriched in cells which had just passed mitosis. Table 4 shows that –
in line with the results presented in 3.6.1 – the fraction of diploid cells contained more
EGFP-positive cells than the fraction of tetraploid cells. This was also observed with
EGFR-targeted polyplexes: All three formulations mediated an approximately three-
fold higher transfection rate in cells which – at the time of data acquisition –
contained a double chromosome set compared to cells with a four-fold chromosome
set. Some of these EGFP-expressing cells had passed mitosis during the time of
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incubation with polyplexes and were therefore more susceptible to nuclear polyplex
import.
Since nuclear membrane integrity is not the only variable during cell cycle
progression, cellular polyplex binding levels were monitored in parallel. This was
considered to be of relevance since endocytic activity, cell size and other parameters
may vary during cell cycle progression.
LPEI 143.3 (+/- 0.0) 294.3 (+/- 0) 181.1 (+/- 4.6) 174.7 (+/- 4.5)
EGF(-) 96.7 (+/- 9.8) 162.8 (+/- 12.4) 151.3 (+/- 3.9) 113.9 (+/- 14.5)
mEGF(+) 143.4 (+/- 7.3) 246.0 (+/- 12.5) 174.7 (+/- 4.5) 174.9 (+/- 13.3)
cellular association (Cy5 median)
diploid cells tetraploid cells EGFP-positive
cells
total
Table 5: Correlation of cellular polyplex association with cell cycle phase and EGFP expression.
Data are derived from the experiment illustrated by Figure 25. Mean values +/- SD of duplicates are
shown.
It revealed that tetraploid cells were able to bind a higher amount of complexes which
might be explained by cell growth during cell cycle progression (Table 5). However,
EGFP-expressing cells were not clearly associated with more polyplexes (Table 5),
indicating that high cellular association might not be directly correlated to successful
transfection.
In summary, EGFR-targeted transfection efficiency in a cell population with a low
percentage of mitotic cells decreased to an extent similar to that of non-targeted
transfection. On the other hand, passing of synchronized cells through mitosis led to
a progression of EGFR-targeted gene transfer efficiency similar to that of non-
targeted transfection efficiency. In line with these results, it was found that the
fraction of diploid cells contained more transfected cells than the fraction of tetraploid
cells. This indicates that EGFR-targeted gene delivery is cell cycle dependent.
3 Results 66
3.5 Clathrin- and lipid raft-dependent endocytosis contribute to
gene transfer by PEI polyplexes
Having proven direct involvement of the EGFR in EGFR-targeted gene delivery (3.3),
it was considered that the receptor might direct the mEGF(+) polyplexes to EGFR-
related endocytosis pathways. Since pathways differ in their ability to deliver the
transgene, this might be another mechanism for enhanced transfection efficiencies of
EGFR-targeted transfection. Internalization of activated EGFRs is known to occur via
both caveolae/raft- and clathrin-dependent endocytosis, depending on the EGF
concentration present (86;87). However, other routes might also be used by EGFR-
targeted polyplexes. To further characterize EGFR-targeted gene delivery, inhibitors
specific to the various endocytosis pathways were employed.
3.5.1 EGFR-targeting does not affect the route of cellular polyplex uptake
To determine the routes of internalization of EGFR-targeted polyplexes,
colocalization studies with specific endocytosis pathway markers were performed.
Hence, cells were incubated with Cy3- or Cy5-labeled polyplexes (LPEI, HBG, N/P 6;
EGF(-); mEGF(+)). Coincubation with Alexa Fluor® 647 transferrin or Alexa Fluor®
488 cholera toxin B (CTB) allowed labeling of the clathrin- or the raft-dependent
pathway, respectively. Living cells were visualized with a confocal laser scanning
microscope (CLSM) and analyzed for colocalization of complexes and markers
(Figure 26).
Notably, polyplexes were found in both types of vesicles, stained with either
transferrin or CTB. About 30 % of mEGF(+) complexes colocalized with transferring,
suggesting that these 30 % had been taken up via clathrin-dependent endocytosis.
About 70 % of the complexes colocalized with CTB and had presumably been
internalized via raft-mediated endocytosis. The same pattern was found with EGF(-)
and LPEI polyplexes, suggesting that neither PEGylation nor incorporation of EGF
influenced the mode of internalization of small polyplexes.
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Figure 26: Colocalization of mEGF(+) (A, B), EGF(-) (C, D) and LPEI (HBG, N/P 6) (E, F) polyplexes
with the pathway markers transferrin and CTB. Alexa Fluor® 647 transferrin and PEI/Cy3-DNA
polyplexes (A, C, E) or Alexa Fluor® 488 CTB and PEI/Cy5-DNA polyplexes (B, D, F) were added to
HUH-7 cells to allow simultaneous internalization. Living cells were visualized 1-4 h after transfection
using a confocal laser scanning microscope. Red: transferrin/CTB. Green: polyplexes.
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3.5.2 Particle size affects cellular uptake pathways of PEI polyplexes
Since all three polyplex formulations were of similar size (LPEI: approximately
100 nm; EGF(-), mEGF(+): approximately 140 nm) (Table 2, Figure 27), it was
considered that cellular polyplex processing mainly depends on the particle size.
Therefore, cellular uptake of small polyplexes (LPEI, EGF(-), mEGF(+)) and large
polyplexes (LPEI, EGF(-)) was analyzed by flow cytometry.
LPEI polyplexes were generated in the presence of salt (OptiMEM = OM) to form
large aggregates of approximately 1 µm in diameter (18). EGF(-) and mEGF(+)
complexes were formed in HEPES buffer (20 mM HEPES, pH 7.1), snap-frozen in
liquid nitrogen and subsequently thawed at room temperature. Since absence of
glucose during the freezing/thawing procedure is known to result in polyplex
aggregation (119), the initially small polyplexes thus grow in size with diameters of
approximately 1-1.5 µm (Figure 27). However, large mEGF(+) polyplexes could not
be tested in this experiment because it was not possible to remove them from the cell
surface. This was probably due to the strong EGFR binding affinity of these
aggregates.
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Figure 27: Particle size of various polyplex formulations in the buffer indicated.
To distinguish between the different endocytosis pathways, cells were preincubated
with specific uptake inhibitors. Chlorpromazine or filipin were used to interfere with
clathrin-mediated or caveolae/lipid raft-dependent endocytosis, respectively. To avoid
albumin binding of the inhibitors (120;121), they were administered in serum-free
medium.
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Figure 28: Cellular uptake of mEGF(+) (HBG) (A), EGF(-) (HBG, HEPES) (B) and LPEI (HBG,
OptiMEM; N/P 6) (C) polyplexes in the presence of endocytosis inhibitors. HUH-7 cells were
preincubated with 10 µg/ml chlorpromazine or 0.5 µg/ml filipin and transfected with Cy5-labeled
polyplexes for 2 h. After removal of extracellularly-bound complexes using heparin, the level of
internalization was assayed by flow cytometry. Black: control. Red: transfection without inhibitor
treatment. Green: chlorpromazine. Blue: filipin.
Neither chlorpromazine nor filipin interfered with cellular uptake of aggregated
polyplexes (LPEI, EGF(-)), indicating that large polyplexes entered the cells via a
third, clathrin- and raft-independent pathway (Figure 28). In contrast, uptake of small
polyplexes (LPEI, EGF(-), mEGF(+)) was reduced by both chlorpromazine and filipin
(Figure 28), confirming that both pathways were involved in the uptake of small
polyplexes by HUH-7 cells (see Figure 26). It was also interesting to note that again,
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neither a change in particle surface potential by PEGylation nor incorporation of a
ligand had an impact on the route of cellular polyplex entry (Figure 26, Figure 28).
3.5.3 Clathrin-dependent endocytosis predominantly mediates gene delivery
in HUH-7 cells
Having established the effects of endocytosis inhibitors on overall cellular polyplex
uptake, it was important to analyze the contribution of each pathway to transfection
efficiency since pathways differ in their ability to deliver the transgene. Therefore,
HUH-7 cells were preincubated for 1 h with either 10 µg/ml chlorpromazine or
0.5 µg/ml filipin and transfected for 2 h with polyplexes in the presence of the same
inhibitor. At these concentrations, cell viability was not affected as shown by MTT
assay (see Figure 32).
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Figure 29: Transfection efficiency of PEI polyplexes in the presence of endocytosis inhibitors. HUH-7
cells were pretreated with 10 µg/ml chlorpromazine or 0.5 µg/ml filipin, transfected with LPEI, EGF(-)
or mEGF(+) polyplexes and luciferase reporter gene expression was determined 24 h after
transfection. Data were corrected by protein content and luciferase activity of control cells without
inhibitor treatment was set as 100 %. Mean values + SD of at least triplicates are shown. ***p < 0.001;
**p < 0.01; *p < 0.05, compared to control cells without inhibitor treatment (ANOVA, Duncan).
Regardless of the formulation used, treatment with chlorpromazine (inhibitor of
clathrin-mediated endocytosis) caused a very pronounced reduction in gene transfer
(by 95-98 %), whereas filipin (inhibitor of the lipid raft-dependent pathway) only
moderately decreased transfection efficiency (by 42-72 %) (Figure 29). Interestingly,
neither PEGylation nor incorporation of mEGF into the polyplex had a detectable
effect on the pathways involved in transfection. This result was surprising since the
various polyplex formulations were expected to be processed by the cells in different
ways. It was also interesting to note that although only one third of small polyplexes
were taken up via the clathrin-dependent pathway (Figure 26), these polyplexes
predominantly mediated successful gene delivery (Figure 29).
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To determine the productive route of aggregated PEI polyplexes, transfection was
carried out as described above.
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Figure 30: Transfection efficiency of PEI polyplexes in the presence of endocytosis inhibitors. HUH-7
cells were pretreated with 10 µg/ml chlorpromazine or 0.5 µg/ml filipin, transfected with aggregated
LPEI, EGF(-) and mEGF(+) polyplexes and luciferase reporter gene expression was determined 24 h
after transfection. Data were corrected by protein content and luciferase activity of control cells without
inhibitor treatment was set as 100 %. Mean values + SD of at least triplicates are shown. ***p < 0.001;
**p < 0.01; *p < 0.05, compared to control cells without inhibitor treatment (ANOVA, Duncan).
Similar to the transfection by small polyplexes (Figure 29), gene transfer by
aggregated complexes was strongly inhibited by chlorpromazine (by 81-94 %) and
only moderately by filipin (by 27-89 %) (Figure 30). This result was surprising since
uptake of aggregated polyplexes had been determined to proceed via a clathrin- and
raft-independent pathway (Figure 28). This suggested that routes might be involved
in the transfection process that do not mediate polyplex uptake itself.
To determine a potential impact of the type of PEI used on the transfection process,
various branched PEI (BPEI) polyplex formulations were tested. These complexes
were approximately 100 nm in size (Figure 27).
Similar to gene delivery by LPEI polyplexes (Figure 29, Figure 30), transfection by
BPEI complexes was strongly inhibited by chlorpromazine (by 95-99 %) and only
moderately by filipin (by 44-78 %) (Figure 31).
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Figure 31: Transfection efficiency of PEI polyplexes in the presence of endocytosis inhibitors. HUH-7
cells were pretreated with 10 µg/ml chlorpromazine or 0.5 µg/ml filipin, transfected with BPEI
polyplexes and luciferase reporter gene expression was determined 24 h after transfection. Data were
corrected by protein content and luciferase activity of control cells without inhibitor treatment was set
as 100 %. Mean values + SD of triplicates are shown. ***p < 0.001; **p < 0.01; *p < 0.05, compared to
control cells without inhibitor treatment (ANOVA, Duncan).
These data suggested that in HUH-7 cells, clathrin-dependent endocytosis
predominantly mediated gene delivery by LPEI and BPEI polyplexes. Neither a
change in particle surface potential by PEGylation nor incorporation of a ligand had
an impact on the route of efficient transfection.
3.5.4 Inhibitors specifically interfere with endocytosis pathways
To confirm the relevance of clathrin-dependent endocytosis for PEI-mediated
transfection in HUH-7 cells, it had to be ruled out that the inhibitors affected
transgene expression on the level of protein synthesis. This potential influence on
luciferase activity was determined by exposing HUH-7 cells stably expressing the
luciferase gene to different concentrations of either chlorpromazine or filipin (Figure
32). Cellular viability measurements (MTT assay) revealed that relative luciferase
activity was not reduced below relative viability at any concentration, indicating that
both inhibitors did not interfere with transgene expression at subtoxic concentrations.
At those concentrations used in the transfection study (Figure 29, Figure 30, Figure
31: 10 µg/ml chlorpromazine and 0.5 µg/ml filipin), neither transgene expression nor
viability were reduced.
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Figure 32: Effect of endocytosis inhibitors on cellular viability (HUH-7) and luciferase activity of HUH-
7 cells stably expressing the luciferase gene. HUH-7 cells and HUH-7 EGFP-Luc cells were treated
with chlorpromazine or filipin for 3 h and incubated with inhibitor-free medium for 22 h. Cells were then
analyzed for viability (MTT assay) and luciferase activity, respectively. The level of control cells was
set as 100 % and mean values +/- SD of duplicates are shown.
To test the specificity of chlorpromazine and filipin, uptake of transferrin and cholera
toxin B (CTB) were analyzed in the presence of endocytosis inhibitors by
fluorescence microscopy (Figure 33). As expected, chlorpromazine prevented only
uptake of transferrin but not that of CTB. By contrast, filipin inhibited only endocytosis
of CTB but not that of transferrin.
These results confirmed that at those concentrations used in the present transfection
studies (Figure 29, Figure 30, Figure 31: 10 µg/ml chlorpromazine and 0.5 µg/ml
filipin), chlorpromazine and filipin specifically and efficiently interfered with the
clathrin- and the raft-dependent pathway, respectively.
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Figure 33: Effect of endocytosis inhibitors on internalization of the pathway markers transferrin and
CTB. HUH-7 cells were pretreated with 10 µg/ml chlorpromazine or 0.5 µg/ml filipin and then
incubated with either fluorescent CTB (Alexa Fluor® 488) or fluorescent transferrin (Alexa Fluor® 647)
to highlight the level of uptake via lipid raft-mediated or clathrin-dependent endocytosis, respectively.
Cells were then visualized by epifluorescence microscopy.
3.5.5 Pathways mediating successful gene delivery vary between cell types
To evaluate whether the clathrin-dependent pathway was also the most relevant in
other cell lines, transfection experiments were performed also in HeLa cells. Since,
however, these cells do not overexpress the EGFR (35,000-65,000 EGFRs/cell
(122)) only the unmodified polyplexes were tested.
HeLa human cervical carcinoma cells were preincubated with either 7.5 µg/ml
chlorpromazine or 1 µg/ml filipin. At these concentrations, cell viability was not
affected (MTT assay, data not shown). Transfection with different PEI polyplex
formulations revealed that in this cell line, blockage of the raft-mediated pathway was
more derogatory to gene delivery than inhibition of the clathrin-dependent pathway
(Figure 34). Accordingly, treatment with filipin caused a strong reduction in gene
transfer (by 41-98 %), whereas chlorpromazine only moderately decreased (by 0-
67 %) transfection efficiency.
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Figure 34: Transfection efficiency of PEI polyplexes in the presence of endocytosis inhibitors. HeLa
cells were pretreated with 7.5 µg/ml chlorpromazine or 1 µg/ml filipin, transfected with LPEI- (A) or
BPEI- (B) based polyplexes and luciferase reporter gene expression was determined 24 h after
transfection. Data were corrected by protein content and luciferase activity of control cells without
inhibitor treatment was set as 100 %. Mean values + SD of triplicates are shown. ***p < 0.001;
**p < 0.01; *p < 0.05, compared to control cells without inhibitor treatment (ANOVA, Duncan).
As opposed to the results obtained in HUH-7 cells, these findings suggested that
intracellular processing of PEI polyplexes in HeLa cells differed from that in HUH-7
cells.
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3.5.6 Pathways mediating successful gene delivery depend on the polyplex
formulation applied
Chlorpromazine and filipin essentially interfere with vital processes in the cell.
Inhibition of clathrin-dependent endocytosis will, for example, impair many receptor-
mediated processes and filipin might – at elevated concentrations – affect all the
processes confined to lipid rafts and eventually destroy membrane integrity.
To rule out artifacts due to inhibitor-induced toxicity, cell viability was assayed in
parallel to reporter gene expression at increasing concentrations of inhibitors (Figure
35). Since PEI-based gene delivery vectors cause significant cellular toxicity (16),
viability measurements were performed in the presence of the corresponding
polyplex formulation. In general, a narrow window of specific inhibitory function and
unspecific toxicity was observed.
Transfection by BPEI polyplexes could be prevented by both inhibitors in HUH-7
(Figure 35B) and HeLa cells (Figure 35D). In contrast, transfection by LPEI
polyplexes in HUH-7 cells could be inhibited only with chlorpromazine but not with
filipin (Figure 35A). In HeLa cells, however, transfection by LPEI polyplexes was
affected by both inhibitors (Figure 35C). These results imply that cellular polyplex
processing depends not only on the cell type but also on the polyplex formulation
applied.
In summary, uptake of small polyplexes into HUH-7 cells was inhibited by
interference with both clathrin- and caveolae/raft-dependent endocytosis. Notably,
neither PEGylation nor incorporation of EGF showed an effect on the mode of
polyplex internalization. In HUH-7 cells, transfection was predominantly inhibited by
chlorpromazine treatment, indicating that the two pathways differed in their ability to
mediate efficient transfection. However, the role of each pathway in gene delivery
depended on both, cell type and polyplex formulation applied.
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Figure 35: Transfection efficiency of PEI polyplexes and cellular viability in the presence of
endocytosis inhibitors. HUH-7 (A, B) and HeLa (C, D) cells were pretreated with chlorpromazine or
filipin and transfected with LPEI (HBG, N/P 6) (A, C) or BPEI (HBS, N/P 10) (B, D) polyplexes. 24 h
after transfection, luciferase activity and cellular viability were determined. Data of transfected control
cells without inhibitor treatment were set as 100 %. Mean values +/- SD of triplicates are shown.
Transfection efficiency data were analyzed for statistical significance. ***p < 0.001; **p < 0.01;
*p < 0.05, compared to control cells without inhibitor treatment (ANOVA, Duncan).
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3.6 Characterization of dynamic interactions of polyplexes with
the cytoskeleton
To enable further analysis of the mechanisms that account for cell type- and polyplex
type-related variations of the transfection process, high resolution live cell imaging
techniques can be employed. Thus, dynamic interactions between the polyplexes
and different parts of the cell can be visualized that help to further characterize the
processes involved.
It was recently proposed that the actin cytoskeleton is involved in the cellular uptake
of PEI polyplexes (43), whereas microtubules were implicated in intracellular particle
transport (67). Therefore, to unravel the role of actin and tubulin filaments in the
process of EGFR-targeted transfection, gene-modified HUH-7 cell lines stably
expressing EGFP-actin or -tubulin chimera were generated. These single cell clones
were isolated from a cell culture containing both transduced and wild-type cells and
were characterized by flow cytometry to comprise a single population with all cells
positive for EGFP (data not shown). In transfection experiments it was ensured that
in these recombinant cells, EGFR-targeting still improved PEI-based gene delivery
(data not shown).
Furthermore, polyplexes were formed containing Cy3- or Cy5-labeled DNA. To
minimize the risk that the Cy-dyes affect the cell-biological behavior of these
complexes, a transfection experiment was performed. It revealed that gene transfer
efficiency of labeled polyplexes was not changed compared to unlabeled particles
(data not shown).
In order to unravel the dynamics of the processes involved, newly developed single
particle tracing techniques were employed (6) which allowed simultaneous
fluorescence imaging of labeled polyplexes and intracellular filaments in living cells.
These measurements were carried out in the group of Prof. Bräuchle (Department for
Physical Chemistry, LMU, Munich) as part of a collaboration project (SFB 486
“Nanoman”). The results with LPEI polyplexes are described in detail in the thesis of
Ralf Bausinger and in (123). The measurements with EGF(-) and mEGF(+)
complexes were performed by Karla de Bruin and Dr. Nadia Ruthardt. The obtained
results are discussed in the discussion part of this thesis (see 4.3).
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4 Discussion
PEI is one of the most efficient nonviral gene delivery vectors both in vitro and in
vivo. However, cellular specificity is necessary to deliver the gene of interest into the
desired cell or tissue. Unmodified PEI polyplexes are not able to distinguish between
target and non-target tissue but rather stick to any cell membrane they reach.
Therefore, systemic administration of PEI polyplexes into the tail vein of a test animal
is always associated with high gene expression in the lung (22) and considerable
systemic toxicity (124). To prevent non-specific trapping, PEI polymers have been
grafted with polyethylene glycol (PEG) which has been shown to reduce cytotoxicity
and significantly prolong circulation time (24). However, gene delivery with
PEGylated polyplexes turned out to be less efficient. To introduce cell specificity and
to restore the transfection efficiency of shielded polyplexes, receptor-mediated
endocytic pathways are being exploited for nonviral gene delivery. For this purpose,
targeting molecules have been incorporated into PEI polyplexes.
The EGFR is a tempting target for gene delivery since it is overexpressed in a wide
variety of human tumors, including HCC. Recently, cryoconservable PEG-shielded
and EGFR-targeted polyplexes were engineered for tumor-directed gene delivery
(37). They were formed by complexing DNA with a mixture of LPEI, PEG(20 kDa)-
PEI22 and a conjugate where mEGF is linked to BPEI via a heterobifunctional
3.4 kDa PEG spacer. In vitro, these EGFR-targeted polyplexes significantly
enhanced gene transfer efficiency into human EGFR-overexpressing HCC cells
compared to non-targeted, PEG-shielded polyplexes (37). They were also able to
target subcutaneous tumors after tail vein injection into HCC xenograft bearing mice
(37). Notably, no acute toxicity was observed in any of these animals. Further
improvement of EGFR-targeted nucleic acid transfer has been achieved recently by
incorporation of endosomolytic melittin into PEG-shielded, EGFR-targeted PEI
polyplexes: This strategy enabled successful elimination of brain cancer
(glioblastoma) after delivery of double-stranded RNA (polyinosine-cytosine [poly IC])
which induced rapid apoptosis in the target cells both in vitro and in vivo (125).
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These findings suggest that EGFR-targeted gene delivery is a promising approach
for the treatment of patients with EGFR-overexpressing tumors. However, until now
the process of EGFR-specific gene delivery has not been characterized in detail.
4.1 Transfection efficiency of EGFR-targeted polyplexes
Strategies towards the development of nonviral vectors for tissue-targeted delivery of
therapeutic genes require the engineering of stable polyplexes that are storable
without significant changes in size, charge or transfection efficiency. Without glucose,
however, large aggregates are formed after the freezing/thawing procedure
(37;126;127). To avoid this, a 5 % glucose buffer was used that allowed freezing and
storage of polyplexes at - 80 °C (Table 2). The glucose obviously served as a
cryoprotectant and was therefore important to avoid aggregation during the
freezing/thawing procedure (119).
Hence, polyplexes met the following requirements for systemic EGFR-targeted gene
delivery: (i) Particle size remained small after thawing (approximately 150 nm). This
is relevant not only for in vivo applications (17) but also for the intracellular
mechanisms of targeted gene delivery since, for example, receptor-mediated
endocytosis requires small particle sizes (17;103). (ii) The PEG-shield reduced the
polyplex surface charge (approximately + 2.5 mV) preventing unspecific interactions
with both blood components and non-target tissue (24). (iii) The EGF linked to the
distal end of a 3.4 kDa PEG chain guaranteed maximum accessibility to its receptor
(126).
Gene transfer studies using a luciferase marker gene construct showed that
mEGF(+) polyplexes mediated enhanced reporter gene expression towards EGFR-
expressing cells (HUH-7, Renca-EGFR) as compared to polyplexes without EGF
(Figure 4). This is in good agreement with previous studies using similar polyplexes
and other cell lines (36;37).
As expected, the percentage of transfected cells increased when EGFR-targeted
polyplexes were applied compared to non-targeted complexes (Figure 8). When
using EGFR-free Renca-LacZ cells, however, no significant difference between
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targeted and non-targeted gene delivery was found (Figure 10), indicating direct
involvement of the EGFR in gene delivery with mEGF(+) polyplexes.
Addition of free EGF as competing ligand before transfection resulted in a decrease
in transfection efficiency of mEGF(+) complexes to nearly the levels of non-targeted
gene delivery (Figure 5, Figure 9). In contrast, transfection efficiency of EGF-free
polyplexes tended to increase in the presence of free EGF. Since rather large
amounts of EGF were used to interfere with EGFR-dependent processes, this effect
is probably due to the mitogenic activity of the free growth factor favoring nuclear
polyplex entry during nuclear disassembly (71;81). However, despite this high
concentration of free EGF, transfection efficiency of EGF(-) complexes did not reach
that of mEGF(+) complexes, indicating that the mitogenic activity of complex-bound
EGF, if at all involved, is not the major reason for enhanced transfection efficiency of
mEGF(+) polyplexes.
These experiments were performed with polyplexes generated with a PEG-PEI
conjugate coupled to murine EGF. Human EGF contains two lysines in the peptide
chain which hampers specific chemical coupling via its N-terminal amino group.
Notably, N-terminal PEGylation does not hinder binding of EGF to its receptor
because the N-terminal residue is located far from the receptor-binding site
(113;114). However, the biological activity of EGF is significantly reduced when
PEGylation occurs at the ε-amino groups of Lys 28 and Lys 48 (113;114). Therefore,
to selectively PEGylate the N-terminal amino group of huEGF, the protein was
modified at a slightly acidic pH (pH 6). This enables selective deprotonation of the N-
terminal amino group since α-amino groups are known to be less basic than ε-amino
groups (114). Gene transfer efficiency of huEGF(+) polyplexes was similar to that of
the corresponding mEGF(+) complexes (Figure 6, Figure 7), indicating that mEGF is
able to substitute huEGF in the design of EGFR-targeted gene delivery vehicles. It
further proved that the huEGF-PEG-PEI conjugate contained a biologically active
EGFR ligand, indicating that the protein was selectively coupled via its α-amino
group.
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4.2 Cellular uptake kinetics of EGFR-targeted polyplexes
Incorporation of receptor-binding ligands into PEI complexes enhances cell binding
and cellular internalization. Under physiological conditions, activated EGFR
complexes are internalized and elevated intracellular EGFR levels can already be
detected less than one minute after stimulation (115). It was therefore expected that
uptake of EGF(+) polyplexes proceeds much faster than that of non-targeted
complexes. Indeed, with a similar polyplex formulation it had been shown previously
that in EGFR-expressing KB cells, EGFR-targeted PEI polyplexes showed enhanced
cellular uptake properties (103). A similar finding was reported with transferrin
receptor-targeted polyplexes in K562 cells (103).
In all these cellular binding studies, labeled DNA was used to stain the polyplexes.
Labeled PEI – although widely used – would have caused artifacts since PEI
polyplex formulations usually contain an excess of PEI that is not complexed to DNA
(16). Improved cellular binding of EGF(+) polyplexes was demonstrated by
transfection of HUH-7 cells on ice when endocytosis was inhibited. Incubating cells at
37 °C for 30 min to 4 h with EGF(+) polyplexes resulted in strong cellular association,
which was two- to three-fold higher as compared to EGF(-) polyplexes (Figure 11).
The difference in cellular association was already pronounced after only 30 min of
incubation, indicating a fast interaction of EGFR-targeted polyplexes with the cell
surface of EGFR-expressing cells. This was probably due to the high affinity
interaction between complex-bound EGF and the EGFR localized in the plasma
membrane.
EGFR specificity was confirmed by transfection of EGFR-free Renca-LacZ cells
which showed no relevant differences in total cellular association between targeted
and non-targeted polyplexes (Figure 13). The small differences in cellular binding at
early time points were probably attributed to small differences in the biophysical
properties of these polyplexes or the presence of low levels of wild-type murine
EGFR on Renca-LacZ cells. Furthermore, binding of EGF(+) polyplexes to HUH-7 or
Renca-EGFR cells was reduced to levels of EGF(-) polyplexes in the presence of
excess free EGF over polyplex-bound EGF (Figure 12), again pointing out the
specificity of interaction. In contrast, addition of albumin as control did not influence
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cell association. Similarly, it has been reported previously that cellular uptake of
transferrin receptor-targeted PEI polyplexes can be significantly reduced in the
presence of excess free transferrin (103).
Fluorescence microscopy of HUH-7 cells transfected with Cy3-labeled polyplexes
revealed that the increased cell binding was also associated with clustering of
EGF(+) polyplexes (Figure 15). EGF(-) polyplexes appeared as a faint punctual
pattern on the cells, whereas EGF(+) polyplexes were observed as large
(micrometer) aggregates associated with the cells. Both, EGF(+) and EGF(-)
polyplexes had a similar particle size prior to transfection, indicating that the
clustering observed was due to the interaction of polyplex-bound EGF with the
EGFR. Clustering of EGFRs after binding of EGF(+) polyplexes could account for this
phenomenon of polyplex aggregation since such clustering has been described for
this receptor family upon ligand binding (128). In addition to the accelerated cellular
binding of EGF(+) polyplexes, the observed aggregation may be an important
mechanism to enhance transfection efficiency. Polyplex aggregation obviously
required specific ligand-receptor interaction and might be another feature contributing
to the enhanced transfection efficiency of EGF(+) polyplexes. Consistent with this
hypothesis, we observed that in incubations of EGF(+) polyplexes with (EGFR-
positive) Renca-EGFR cells or (EGFR-negative) Renca-LacZ cells, only Renca-
EGFR cells mediated clustering of polyplexes (Figure 15).
Quantification of internalized complexes revealed that already within 30 min, the
majority of cells had taken up a significant amount of EGF(+) polyplexes
(approximately 81 %) (Figure 16A, Figure 17A) whereas cellular entry of EGF(-)
polyplexes was very slow and only detectable after approximately 2 h (approximately
62 % Cy5-positive cells) (Figure 16B, Figure 17A). Similarly, LPEI polyplexes (HBG,
N/P 6) were taken up by the cells to a significant extent only after 2 h (approximately
77 % Cy5-positive cells) (Figure 16C, Figure 17A) – despite their favorable cellular
binding properties (Figure 16C).
The results in Figure 16 and Figure 17 thus revealed characteristic differences
between the three formulations. 30 min after transfection, total cellular association
levels (regarding both Cy5 fluorescence intensity and percentage of Cy5-positive
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cells) showed the following ranking: EGF(+) > LPEI >> EGF(-), whereas
internalization levels were observed as follows: EGF(+) >> LPEI > EGF(-). This
demonstrated that cellular uptake of the two non-targeted formulations occurred very
slowly – in contrast to that of the targeted formulation. All three polyplexes had a
similar particle size (approximately 100-150 nm), indicating that this property did not
account for the variations observed. However, they showed different particle surface
charges: LPEI polyplexes display a net positive surface potential (approximately
+ 20-30 mV) facilitating binding to the negatively charged cell membrane (Figure
16C), whereas EGF(-) complexes are nearly neutrally charged (approximately
+ 2.5 mV) causing low cellular association (Figure 16B). Despite these differences,
uptake kinetics were slow in both cases. In contrast, EGF(+) complexes showed
cellular binding characteristics similar to that of LPEI (Figure 16A, C), however,
internalization was evident already within 30 min (Figure 16A, Figure 17A, B). This
proves that EGFR-targeted complexes, once attached to the cell, are taken up
indeed very fast. This finding fits well into the lines of evidence that receptor-
mediated endocytosis is a fast process (85;115). Under physiological conditions,
elevated intracellular EGFR levels have already been detected less than one minute
after stimulation (115). Accordingly, uptake of EGF-containing polyplexes was found
to proceed also within a few minutes (Figure 16A, Figure 17A, B). In contrast, LPEI
polyplexes with similar cellular association characteristics showed slow uptake
behavior similar to slow-binding EGF(-) complexes (Figure 16C, Figure 17A, B),
indicating that unspecific uptake through adsorptive endocytosis is less efficient and
requires extended periods of time to reach the same degree of internalization. Similar
results have been previously reported in a study where cellular uptake kinetics of
transferrin receptor- and CD3 receptor-targeted complexes had been related to that
of non-targeted PEI polyplexes (103).
Interestingly, cellular uptake velocity (i. e. increase in Cy5 fluorescence intensity over
time) of EGF(+) complexes was not constant over the 4 h period as observed with
the non-targeted formulations (Figure 17B). The slope of the curve during the first
30 min was 10-times higher than that of the rest of the curve. Notably, two pathways
of EGFR internalization exist: a saturable route via clathrin-coated pits and a
constitutive route via clathrin-independent endocytosis which is 5- to 10-times slower
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(86;87;129). Since uptake velocity of EGF(+) polyplexes dropped down very early in
transfection, one might speculate that this was due to an EGF-induced
downregulation of the inducible pathway leaving the slow constitutive pathway intact.
Fast cellular polyplex uptake suggests that the onset of reporter gene expression is
also accelerated. A time course experiment confirmed this assumption. Already 4 h
after transfection with luciferase-encoding EGF(+) polyplexes, luciferase activity
could be detected (Figure 18). This result strongly suggests that accelerated polyplex
uptake is an important mechanism for enhanced transfection efficiency of EGFR-
targeted PEI polyplexes.
All these cellular binding and uptake kinetics data imply that EGFR-targeted
polyplexes bind to the EGFR and are internalized by the cells via receptor-mediated
endocytosis. The interactions of polyplexes with HUH-7 cells were therefore studied
by single particle ultrasensitive fluorescence microscopy experiments by our
collaboration partners in the the group of Prof. Bräuchle (Physical Chemistry, LMU).
Since involvement of the cytoskeleton in PEI-based gene delivery had been
proposed recently (43;67), HUH-7 cells stably expressing EGFP-actin or EGFP-
tubulin chimera were generated for these experiments.
4.3 Dynamic interactions of polyplexes with the cell
Details on single particle fluorescence microscopy experiments using LPEI
polyplexes can be found in (123) and in the thesis of Ralf Bausinger (in preparation).
Experiments using mEGF(+) and EGF(-) polyplexes were performed by Karla de
Bruin and Dr. Nadia Ruthardt.
First observations of time-lapse and stream recordings revealed typically three
different motion kinetics for particles interacting with the cells: immobility, diffusion,
and directed motion.
For a typical mEGF(+) polyplex, after docking onto the plasma membrane, a first
phase of immobility was observed. Slow movement of the particle during this phase
can be attributed to movement of the plasma membrane generated by the underlying
cortical actin network. This was also supported by the correlated movement of
several particles in close proximity. After a certain time – entering the second phase
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– the particle started to move independently of the underlying plasma membrane
movement. In this phase, diffusion was observed and could be distinguished from the
immobility phase by increased step length distribution. Whether or not the particle
had been internalized at this time point remained unclear. The third phase was
defined by occurrence of directed motion. In this case, the step length increased
further and particles showed highly directed motion for several frames interrupted by
phases of diffusion. These phases of directed motion were typical of the transport by
motor proteins. The straight trajectories indeed suggested transport along
microtubules. However, further studies are required to determine whether this
transport takes place along these microtubule filaments.
Movies with EGF(+) polyplexes in HUH7 cells expressing actin-GFP also revealed
particle movement by actin tails which might indicate presence of the particle in an
endosomal vesicle. By comparing the values of the diffusion coefficient D and the
velocity v during the different phases of a statistically significant number of
trajectories, the motion characteristics will be determined in greater detail. This
should allow identification of the motor proteins and cytoskeletal elements involved
and eventually the prediction whether the particle is inside or outside the cell.
In contrast to the tight binding of EGF(+) polyplexes to the plasma membrane,
several EGF(-) particles did not exhibit the immediate immobility after touching the
plasma membrane. Instead, particles diffused back into the medium. For EGF(-)
particles, immobility combined with movement generated by plasma membrane
dynamics as well as diffusion was also observed. However, it remained unclear
whether the early diffusive motion of EGF(-) particles occured along or bound to the
plasma membrane or even within the cytosol after internalization.
Analysis of the movies with EGF(+) and EGF(-) particles revealed a difference
regarding the onset of directed motion. When defining directed motion as an
indication for motion along microtubules in the cytosol and therefore for successful
internalization, the time by which more than 50 % of EGF(-) particles were
internalized seemed to be longer than in the case of EGF(+) polyplexes.
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For quantitative data in a statistically significant range, quantitative movie analysis of
the particle trajectories in detail is necessary. As this work is in progress, more
measurements will be conducted to obtain adequate movies for analysis.
These results are in good agreement with the flow cytometry data since they imply
that cellular uptake of EGFR-targeted polyplexes proceeds faster than that of non-
targeted polyplexes. A further indication for involvement of the EGFR in cellular
binding of EGF(+) polyplexes was the immediate immobility and the tight binding of
the particles to the plasma membrane despite the particle´s low surface charge.
Several EGF(-) complexes obviously did not exhibit the immediate immobility after
touching the plasma membrane. Instead, particles easily detached from the
membrane and diffused back into the medium which is due to their low surface
charge impairing adsorptive electrostatic interaction with the negatively charged
plasma membrane. This is in line with the slow cellular association of EGF(-)
polyplexes as observed by flow cytometry (see Figure 11, Figure 16). Similarly, the
slow internalization of PEG-shielded complexes (see Figure 17B) was supported by
the observation that the time by which more than 50 % of EGF(-) particles were
internalized seemed to be longer than in the case of EGF(+) polyplexes.
Additional measurements are being conducted to further characterize the processes
involved in EGFR-targeted and non-targeted gene delivery. Correlation of the
particles´ movements with cellular components like the actin and tubulin network will
be of particular value to further understand the sequence of events leading to
transfection. Similar experiments with LPEI polyplexes already delivered insight into
the role of the cytoskeleton in PEI-mediated gene delivery (published in (123)).
In these experiments, LPEI polyplexes (HBG, N/P 6, approximately 100 nm in size)
were found attached to the cell surface within 10 min after transfection. The largest
fraction of observed polyplexes was found organized in filamentous arrays along the
actin fibers (Figure 36A) and showed strongly reduced diffusion coefficients. In a
number of cases, active transport with or along actin filaments was observed. This
movement implied that actin filaments were involved in the cellular entry of
membrane-bound LPEI polyplexes.
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Figure 36: Interaction of LPEI polyplexes (HBG, N/P 6) with cytoskeletal filaments in HUH-7 cells.
(A) Interaction of polyplexes with actin structures during the early stage of transfection. Cy3-labeled
polyplexes and EGFP-actin filaments were simultaneously imaged by fluorescence microscopy.
(B) Active transport of polyplexes along microtubules. Cy3-labeled polyplexes and EGFP-labeled
microtubules were simultaneously imaged by fluorescence microscopy (scale bar: 5 µm). (in
collaboration with Ralf Bausinger, published in (123))
Polyplex observation at a later stage of transfection revealed a distinctly different
motion behavior. Its hallmarks were long range directed motion with increased
velocities. Experimental data showed that the polyplex movement occured along
tracks which were given by the microtubules (Figure 36B).
It is an intriguing question, in what form the polyplexes are undergoing this fast
transport. Coincubation of LPEI polyplexes and the fluid phase marker dextran-Alexa
Fluor® 647 revealed that all the fast moving polyplexes were found inside vesicles.
Transport of vesicles along microtubules is known to be mediated by molecular motor
proteins such as kinesins or dyneins. Accordingly, the maximum velocity of the
polyplex movement (vmax = 0.65 µm•s-1) was found to compare well with those
reported for kinesin and dynein (67;130). Notably, polyplexes were found to change
the direction of motion very fast, suggesting that both kinesin (moves towards the [+]
end of the microtubule) and dynein (moves towards the [-] end of the microtubule)
were involved.
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4.4 EGFR activation by EGFR-targeted polyplexes
To further characterize the cellular mechanisms of EGFR-targeted gene delivery,
direct involvement of the EGFR had to be proven. The observation that both reporter
gene expression and cellular polyplex association could be inhibited by addition of
free competing ligand (Figure 5, Figure 7, Figure 9, Figure 12) had already
suggested that the EGFR is involved in the cellular uptake of EGF(+) polyplexes.
This was further supported by the finding that upon EGFR-targeted transfection,
EGFR-free Renca-LacZ cells showed neither enhanced cellular polyplex association
(Figure 13) nor improved reporter gene expression (Figure 10).
Western blot analysis revealed that binding of mEGF(+) polyplexes to the EGFR also
entails receptor activation. This is of relevance since EGFR activity controls a wide
variety of biological responses. Shortly after transfection with EGF(+) polyplexes,
EGFR and Akt were converted into their activated form by phosphorylation (Figure
20). This verified that EGF(+) polyplexes bind to the receptor and implied that the fast
uptake of mEGF(+) polyplexes is mediated by the EGFR. In the cell line tested,
elevated phospho-Erk levels were already detectable under control conditions – in
contrast to EGFR and Akt. Since Erk is known to activate the transcription of genes
involved in cell growth and proliferation (131), it has been implicated in tumor cell
proliferation and seems to be constitutively activated in HUH-7 hepatoma cells.
mEGF(+) polyplexes then induced a decrease in phospho-Erk levels below the level
of untreated control cells. This was surprising since it is widely agreed that EGFR
activity mediates activation of the Ras- Raf- Erk signaling pathway (131). Inactivation
of phospho-Erk is associated with the activity of MAPK phosphatases (MKPs, also
called “dual specificity phosphatases” (DSPs)) which dephosphorylate MAPKs (Erk,
p38, JNK) and thus control duration and extent of MAPK activity (132). These
enzymes show substrate specificity for all three MAPK but to a varying extent. As
part of a negative feedback mechanism they are activated by the substrates
themselves (132;133). Here, MKPs were probably induced by the strong EGFR
activation in order to balance Erk activity. This can explain why phospho-Erk levels
decreased after stimulation with both EGF(+) complexes and free mEGF.
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Activation of EGFR and its downstream signaling pathways is of high relevance for
therapeutic applications because EGFR activity controls cell proliferation and has
been implicated in the pathogenesis of many solid tumors. Akt (= protein kinase B) –
also called “survival kinase” – has been shown to promote cell survival. Thus, EGF(+)
polyplex binding to EGFR-expressing cells might induce cell proliferation or even
prevent cell death. Consequently, activation of these signaling pathways by EGFR-
targeted PEI polyplexes may not be desirable in the treatment of tumors. However,
considering the transfection process of PEI polyplexes, this conclusion has to be re-
evaluated since EGFR-targeted gene delivery was shown to be more efficient in
dividing cells (Figure 22). Notably, the first pulse of EGFR signaling is known to
induce exit from quiescence into G1 phase and appears to render cells responsive to
subsequent mitogenic stimulus (83). Therefore, stimulation of the EGFR might
indeed be of advantage in order to enhance transfection efficiency. Furthermore,
gene therapy of tumors aims at eliminating the malignant cells. Initiation of cellular
proliferation in dying cells will therefore be of less relevance. Notably, successful
elimination of EGFR-overexpressing tumors by systemic EGFR-targeted nucleic acid
delivery has already been reported (125). Similarly, if gene therapy has to be
combined with chemotherapy, EGFR activation seems to be desirable since
chemotherapy only attacks cells that are in the process of cell division. Cells that are
at rest are much less vulnerable to chemotherapeutic damage. Induction of cell cycle
progression in response to EGFR activation might therefore be useful in the
chemotherapeutic treatment of cancer. Nevertheless, this concept has to prove
successful in the clinical setting since EGFR overactivity was also found to be
associated with resistance to cytotoxic drugs and radiotherapy (121).
It has to be considered that both EGFR activation and signaling are processes
strongly dependent on the ligand concentration (86;87;134). Here, a polyplex
concentration of 6 µg DNA per ml was chosen which corresponds to a mEGF
concentration of approximately 120 ng/ml. Compared to the physiological range of
huEGF levels (1-2 ng/ml huEGF in serum; 10-100 ng/ml huEGF in several other
biological fluids) (87), this concentration is indeed very high which accounts for the
noticeable activation of EGFR signaling by both EGF(+) polyplexes and free mEGF
(Figure 20). However, the polyplex concentration that can be reached in a human
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being will probably be clearly below the one used here in vitro. The pharmacological
relevance of this finding will therefore only be assessable in the clinical setting.
Furthermore, reduction of the content of biologically active EGF in this polyplex
formulation can be achieved by removal of free EGF-PEG-PEI conjugate through
removal of free PEI by a method which has been reported recently (16). This will help
to further improve the safety profile of this very promising strategy.
Since overexpression of EGFR correlates with increased metastasis, decreased
survival and a poor prognosis, agents targeting these receptors and their
downstream signaling pathways (e. g. Erk) are now being evaluated in the clinic.
Cetuximab (Erbitux®), for example, is an IgG1 monoclonal antibody and has been
approved for the treatment of advanced metastatic colorectal cancer. It operates by
locking onto the external domains of the EGFR of cancer cells which prevents normal
EGF from stimulating cell growth (135).
Accordingly, EGFR-binding antibodies (like cetuximab) can be used alternatively to
target gene delivery vectors to EGFR-overexpressing cells while preventing EGF-
induced receptor activation and downregulation. However, EGFR
autophosphorylation is known to be essential for internalization via the rapid clathrin-
dependent route which is induced by ligand occupancy (129;136). Since cetuximab
does not induce EGFR activation, such vectors should only be internalized through
the constitutive clathrin-independent pathway which is 5- to 10-times slower
(129;136). Nevertheless, this concept will be of interest because EGFR activation
and downregulation would be avoided. In this respect, application of EGF(+)
polyplexes might emerge as a “double-edged sword”.
4.5 Cell cycle dependency of EGFR-targeted gene delivery
Recently it was reported that the EGFR after stimulation with EGF is able to
translocate to the nucleus and modify sequence specific gene expression (92;137).
This nuclear localization was observed in different cell lines and tissues including
many human cancers and was found to be associated with the highly proliferating
status of these cells (137). Interestingly, cyclin D1 – a cell cycle regulator essential
for G1 progression – was identified as one of the targets of nuclear EGFR (92).
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Since nuclear entry of nonviral vectors is known to be a major bottleneck to efficient
transfection, the possibility was considered that EGF mediates enhanced nuclear
accumulation of the polyplexes. For polyplex-mediated gene delivery, the major path
to nuclear entry seems to be via nuclear disassembly during mitosis (71). If, however,
EGF has a significant effect on nuclear import, this cell cycle dependency should be
less pronounced when using EGFR-targeted polyplexes.
Therefore, to determine whether EGFR-targeted polyplexes are able to efficiently
transfect postmitotic cells, the number of dividing cells was reduced by a single
thymidine block (Figure 21). Transfection in the presence of thymidine revealed that
reporter gene expression of LPEI (HBS ½, N/P 6), EGF(-) and EGF(+) polyplexes
decreased to a similar extent (Figure 22), indicating that EGFR-targeted complexes
are not more efficient in transfecting postmitotic cells than non-targeted polyplexes.
Notably, in transfection experiments using elutriated HeLa cells, similar polyplexes
(LPEI, OptiMEM, N/P 6) had already been shown to display moderate cell cycle
dependency: cells that were allowed to undergo mitosis during transfection yielded
up to 11-fold higher transfection efficiencies than cells that did not divide (72).
Admittedly, centrifugal elutriation allows a better separation of cell fractions than a
thymidine block. In the present study, up to 5 % were constantly cycling through
G2/M phase (Figure 21) and might have undergone cell division during the
transfection process. Notably, three further undesired side effects probably led to
artifacts: thymidine causes cellular toxicity, but it might also affect transgene
expression on the level of protein synthesis and/or the transfection process itself. To
estimate the consequences of the first two effects, HUH-7 EGFP-Luc cells were
cultured in the presence of thymidine for the time of the complete experiment (34 h)
and analyzed for luciferase activity. In these cells, luciferase activity was found to be
62.3 % (+/-2.3 %) of untreated control cells (data not shown). This control
experiment, however, provided only a rough estimation of the relevance of these
undesired thymidine effects and did not detect possible interference with the
transfection process (beyond reduction of mitosis). Therefore, the data in Figure 22
can only be regarded as a rough indication for the role of mitosis in EGFR-targeted
gene delivery.
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To further evaluate the impact of mitosis on EGFR-targeted gene delivery, cells were
synchronized and transfected 4 h after thymidine release. Analysis of cell cycle
progression revealed that the cells underwent mitotic cell division between 12 h and
20 h after thymidine removal (Figure 23). 12 h after transfection (i. e. 16 h after
thymidine release), transgene expression could be detected regardless whether non-
targeted (LPEI, HBS ½; EGF(-)) or targeted polyplexes were used (Figure 24). This
indicates that breakdown of the nuclear membrane is an important process during
EGFR-targeted gene delivery. This was further supported by the observation that all
polyplexes mediated a very similar progression in expression of both EGFP and the
luciferase reporter gene (Figure 24C, D). The data therefore imply that mitosis is as
important in EGFR-targeted gene delivery as it is in non-targeted transfection. This
means that complex-bound EGF is not able to mediate efficient nuclear accumulation
of EGFR-targeted polyplexes.
To obtain further evidence for the cell cycle dependency of EGFR-targeted gene
delivery, cell cycle, reporter gene expression and total cellular association were
monitored in parallel. Thus, no chemical drug had to be added that caused artifacts.
This revealed that 6 h posttransfection, the fraction of diploid cells contained three-
fold more EGFP-expressing cells than the fraction of tetraploid cells (Figure 25, Table
4). Since the fraction of diploid cells was expected to be enriched in cells that had
passed mitosis during the 6 h incubation with polyplexes, it was concluded that this
fraction was more susceptible to nuclear polyplex import. No difference between
EGFR-targeted (EGF(+)) and non-targeted polyplexes (LPEI, HBS ½; EGF(-)) was
evident, indicating that – in line with Figure 22 – mitosis is as important in EGFR-
targeted gene delivery as it is in non-targeted gene delivery.
Although there is some historical evidence that GFP expression may be toxic to
mammalian cells (138) and lead to a delay in cell cycle progression at G1 phase, it is
now generally assumed that low to moderate expression of GFP is minimally
perturbing to the host cell (118;139;140). Since in the present study (Figure 25, Table
3, Table 4, Table 5), transfection levels were low – due to the short incubation time –
it can be assumed that EGFP did not affect cell cycle progression.
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The cell cycle dependency observed in this study indicates that EGF is not able to
mediate efficient nuclear polyplex translocation. This process is either not available
for EGFRs bound to EGF(+) polyplexes or it is possible but just not efficient enough
to enhance transfection efficiency. It is difficult to explain why EGFRs are not able to
(efficiently) translocate PEI polyplexes to the nucleus since the route(s) by which the
EGFR moves into the nucleus have not been clearly elucidated yet (137). The
process might show only a low capacity; or vesicles containing PEI polyplexes are
processed by the cell in a different way than those which contain physiological
EGF/EGFR complexes. This could be due to the PEI polyplexes affecting vesicular
pH (see 1.3.2.2, (141)), vesicle size or internalization pathway. Moreover, other
conditions might have to match. Since the EGF concentration present has been
shown to affect the pathway of internalization (86;87), it is conceivable that it also
affects nuclear translocation of the cargo. A further possible reason might be that
coexistent signals are required for this process of EGFR-mediated nuclear
translocation.
The advantage of this cell cycle dependency is the fact that in adults, most of the
body´s cells are not dividing. These cells spend most of their time in a resting state
and only divide if damage repair is necessary. Tumor growth, however, is very fast.
Transfecting only dividing cells can therefore be regarded as a kind of passive tumor
targeting. Admittedly, not all tumor cells are constantly dividing but some cancer cells
might be resting. These cells will be less susceptible to gene therapy treatment by
EGFR-targeted PEI polyplexes. Though, this in turn depends on the fact whether at
those concentrations reached in vivo, polyplex-bound EGF is able to induce cell
proliferation (see 4.4).
To enable efficient gene delivery also in non-dividing cells, further components can
be incorporated into the vector. For example, signal-mediated active transport
mechanisms have been exploited for trafficking vectors to the nucleus. Covalent
coupling of a single NLS peptide to a CMV-Luciferase gene led to an up to 1000-fold
enhancement in transfection efficiency presumably attributed to improved nuclear
translocation by the nuclear import machinery (73). In this way, it will be possible to
generate an artificial virus-like vector carrying domains for both cell-
specific/enhanced uptake and improved nuclear polyplex/transgene accumulation.
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4.6 Mode of cellular polyplex uptake
Despite various studies investigating the mechanisms of uptake and intracellular
trafficking (41-43;45;46;51;123), current understanding of the processes involved in
cellular uptake of PEI polyplexes is still limited. Following previous findings that
HSPGs are involved in the cellular uptake of PEI polyplexes (45;56), it was recently
proposed that syndecan-mediated polyplex binding triggers actin-driven
internalization via a mechanism related to macropinocytosis (43). In addition, recent
studies reported on the close relation between particle size and internalization
pathway (41;51) where either caveolae, lipid rafts, clathrin-coated pits or membrane
ruffles were involved. Regarding these relations, however, reports remain
controversial. Since mEGF(+) complexes had been shown to directly bind to the
EGFR (Figure 19, Figure 20) it was assumed that EGF affects these modes of
uptake and thus the way of intracellular polyplex processing.
Colocalization experiments of the pathway markers transferrin and CTB with small
LPEI, EGF(-) and EGF(+) polyplexes revealed involvement of both clathrin- and raft-
dependent endocytosis in the cellular uptake of small polyplexes (Figure 26). Most
remarkably, neither a change in particle surface potential by PEGylation nor
incorporation of EGF as a ligand had an impact on the route of cellular polyplex
entry. This result was surprising since the various polyplex formulations were
expected to be processed by the cells in different ways which in turn was suggested
by their different biophysical properties, their diverse molecular composition and,
most remarkably, by their different binding and uptake kinetics (as illustrated by
Figure 16, Figure 17).
Since all three polyplex formulations were of similar size (LPEI: approximately
100 nm; EGF(-), mEGF(+): approximately 140 nm) (Table 2, Figure 27), it was
concluded that cellular polyplex processing mainly depends on the particle size.
Notably, close relation between particle size and internalization pathway had been
proposed recently (41;51). This size dependency probably accounts for the similar
results with different polyplex formulations (Figure 26, Figure 28) and further
suggests that both pathways are utilized by the polyplexes because of a coexistence
of small and medium-sized particles during transfection (Figure 26, Figure 28). The
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PEGylated polyplexes formed in HBG (EGF(-), EGF(+)) had an initial size of
approximately 100-200 nm and were therefore in the size range for uptake via both
clathrin- and caveolae/raft-mediated endocytosis (41;51). LPEI polyplexes had an
initial size of approximately 100 nm. In transfection medium, however, salt-induced
aggregation of unshielded PEI polyplexes occurs (18) which is known to result in a
mixture of differently sized particles (17). To test the aggregation behavior under
transfection conditions, HUH-7 cells were incubated with Cy3-labeled polyplexes and
visualized for 2 h by fluorescence microscopy (data not shown). Due to very fast
cellular binding, particles grew only slightly in size (approximately up to 300 nm).
Assuming different pathways for differently sized particles (41;51), this mixture of
small and medium-sized polyplexes (17) (ranging from approximately 70 to 300 nm)
probably accounts for the observation that both clathrin- and raft-dependent
endocytosis mediate cellular uptake of these polyplex formulations (Figure 26, Figure
28).
In contrast, large polyplexes (LPEI, EGF(-)) were taken up by the cells via a third,
clathrin- and raft-independent pathway (Figure 28). This was concluded since uptake
of aggregated polyplexes was affected neither by chlorpromazine nor by filipin.
Accordingly, endocytic and non-endocytic processes could be involved. One possible
internalization pathway for aggregated LPEI and EGF(-) polyplexes is
macropinocytosis which has been proposed to mediate uptake of large complexes
(> 200 nm) (51). Interstingly, this pathway has also been implicated in polyplex
uptake by a human hepatoma cell line (46). It is further known that the high charge
density of unshielded PEI polyplexes is capable of inducing local membrane damage,
especially when large aggregates interact with the plasma membrane (55). In the
case of PEG-shielded EGF(-) complexes, this mechanism will be less relevant
because of their nearly neutral surface charge.
Figure 28 thus supports the hypothesis that the capacity of internalization pathways
is mainly limited by the particle size and not by other particle properties like surface
charge or molecular composition. Nevertheless, regarding the small polyplexes, the
similar results with the three different polyplex formulations can also be mere chance:
PEI polyplexes with a size of 80-200 nm (LPEI, EGF(-), EGF(+)) are small enough for
both, caveolae/raft-mediated and clathrin-dependent endocytosis (51). These
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pathways happen to be the same as those involved in the physiological
internalization process of EGF/EGFR complexes. It therefore remains elusive
whether particle size is indeed the all-dominant factor defining the cellular
internalization route of PEI polyplexes. Uptake studies with differently sized
polyplexes of defined diameter and varying composition will be necessary to address
this question.
4.7 Pathways mediating successful transfection
Since pathways obviously differ in their way to deliver transgenes (42;46;51;52),
pathways were determined that mediate successful gene transfer of the various
polyplex formulations. Previously, it was reported that lipoplex-mediated transfection
occurs through the clathrin-dependent pathway of endocytosis (42;52). However,
less is known about the relative contribution of each pathway to gene transfer
efficiency mediated by PEI polyplexes. Rejman and coworkers recently addressed
this issue and proposed that only the caveolae/raft-mediated pathway leads to
efficient transfection of BPEI polyplexes (42).
To test whether this route is also the most relevant in EGFR-targeted gene delivery,
transfection experiments were performed in the presence of specific endocytosis
inhibitors. They revealed that in HUH-7 cells, clathrin-dependent endocytosis
predominantly mediates transfection by EGFR-targeted as well as PEG-shielded and
unmodified PEI polyplexes (Figure 29, Figure 30, Figure 31). This result was
surprising since – although the various polyplex formulations had been found to be
taken up via the same pathways (see Figure 26, Figure 28) – they were at least
expected to be processed by the cells in different ways. Small polyplexes can be
taken up into small vesicles, whereas aggregated polyplexes are either confined to
large vesicles or might exploit non-endocytic pathways for efficient cellular entry (as
discussed in 4.6) (51;55). Furthermore, large polyplexes are expected to exert a
stronger proton sponge effect than small polyplexes, due to a higher PEI content
(17;142). PEG-shielded complexes are known to display weak cellular binding
properties (Figure 11, Figure 16) and probably have reduced ability to force
endosomal rupture (143). In contrast, EGFR-targeted polyplexes are expected to
enter the cells via EGFR-related pathways, namely clathrin- and caveolae/raft-
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dependent endocytosis (86;87). Aggregated EGFR-targeted polyplexes, on the other
hand, will show strong cellular association due to EGFR binding but can not be
internalized via EGFR-related pathways since clathrin- and caveolae-derived vesicles
are limited regarding their size. This had been observed, for example, with large
transferrin receptor-targeted PEI polyplexes which displayed improved cellular
binding characteristics but only sparse internalization, probably because they were
too large for transferrin-mediated clathrin-dependent endocytosis (103).
Figure 29, Figure 30 and Figure 31 thus revealed that in PEI-mediated transfection of
HUH-7 cells, the clathrin-dependent pathway has a much better ability to efficiently
deliver the transgene than the raft-dependent route. Although only 30 % of small PEI
(LPEI, EGF(-), EGF(+)) polyplexes were taken up by HUH-7 cells via clathrin-
dependent endocytosis (Figure 26), these 30 % of particles predominantly mediated
successful transfection (Figure 29). It can therefore be concluded that the polyplexes
taken up via these two pathways are processed by the cells in different ways. This is
indeed conceivable since each endocytic pathway serves different tasks and
therefore bears its own characteristics which favor or impair intracellular polyplex
trafficking.
Considering the biophysical properties of PEI (e. g. their buffering capacity), the
differences in vesicular pH between the clathrin- and the raft-dependent pathways
probably play an important role in PEI-mediated gene delivery and might account for
these differences. Caveolar vesicles and caveosomes have a neutral pH (49). In
contrast, clathrin-coated vesicles – after loosing their clathrin coat – become acidified
leading to the formation of early (pH ~ 6) and late endosomes (pH ~ 5) which
ultimately fuse with lysosomes (pH ~ 4.5) (47). Although controversial data exist
whether PEI polyplexes can be found in lysosomes (55;144;145) it is widely agreed
that the strong endosomal buffering capacity of PEI can lead to enhanced endosomal
escape (19;44;60). Consequently, blockage of endosomal buffering with bafilomycin
resulted in a substantial decrease in reporter gene expression (60), indicating that
successful gene expression of PEI polyplexes occurs through vesicles that acidify. It
is therefore conceivable that in HUH-7 cells, uptake of PEI polyplexes via clathrin-
dependent endocytosis favors efficient transfection (Figure 29, Figure 30, Figure 31).
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Transfection data of large PEI polyplexes (Figure 30) further suggest that pathways
can also favor successful gene delivery without being directly involved in cellular
polyplex uptake. Aggregated polyplexes (LPEI, EGF(-)) were taken up by the cells
via clathrin- and raft-independent pathways (Figure 28), whereas transfection was
strongly affected by chlorpromazine (Figure 30). This implies that routes might be
involved in the transfection process that do not mediate uptake of these polyplexes
and further suggests that in the transfection process of aggregated PEI polyplexes,
the clathrin-dependent pathway plays an important role at a later stage of
transfection. It is, for example, conceivable that crosstalk or traveling between the
internalization pathway and the clathrin-dependent route exist which might then
trigger polyplex escape into the cytosol. In this way, clathrin-mediated endocytosis
might favor efficient transfection without being directly involved in cellular polyplex
uptake. Furthermore, aggregated PEI polyplexes are very heterogeneous in size with
small particles of 100 nm and aggregates in the micrometer range both being present
in the same solution (17). The possible conclusion that the moderate effect of
inhibitors on the transgene expression of aggregated polyplexes (Figure 30) is
partially due to interference with the fraction of small-sized polyplexes, however, is
not plausible. The reason is that this theory - where the fraction of small particles
predominantly mediates gene transfer by aggregated polyplexes – contrasts with the
finding that in general, transfection by aggregated polyplexes is much more efficient
than that by small complexes (17;18).
Interestingly, different results had been reported recently regarding the importance of
the clathrin-dependent pathway in PEI-mediated gene delivery. They suggested that
only caveolae/raft-mediated uptake contributes to efficient transfection by PEI
polyplexes in HeLa cells (42). It can therefore be concluded that cell-specific
differences in intracellular polyplex trafficking exist. Transfection experiments in HeLa
cells verified this conclusion since here – opposed to the data with HUH-7 cells – the
raft-mediated pathway was more relevant (Figure 34). Notably, similar experiments –
performed by our collaboration partners Roosmarjin Vandenbroucke and Dr. Niek
Sanders (Ghent University) – revealed that COS-7 (african green monkey kidney)
cells show a pattern similar to HUH-7 cells since gene transfer is predominantly
mediated by the clathrin-dependent pathway. Taken together, these findings suggest
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that HeLa cells process PEI polyplexes in a different way than HUH-7 and COS-7
cells. However, since nearly all cells are specialized for certain functions which
require different actions within the cell, it is indeed conceivable that different cell lines
differ in their way to process the same material.
Since working concentrations of the inhibitors were very close to toxicity, cellular
viability and reporter gene expression were assayed in parallel at increasing
concentrations of inhibitors (Figure 35). As PEI-based gene delivery vectors cause
significant cellular toxicity (16), viability measurements were performed in the
presence of the corresponding polyplex formulation. In general, a narrow window of
specific inhibitor function and unspecific toxicity was observed, emphasizing that a
high level of caution had to be exercised to distinguish between specific and
unspecific effects.
The results revealed that cellular polyplex processing depends on both, the cell line
and the polyplex formulation applied (Figure 35). Most remarkably, LPEI-mediated
transfection in HUH-7 cells was not susceptible to filipin, whereas internalization had
been shown to occur via both pathways (Figure 26, Figure 28). Filipin acts by
sequestering cholesterol within a complex in the plasma membrane and thus inhibits
uptake via both caveolae and lipid rafts (54). HUH-7 and other hepatoma cell lines
are known to be caveolin-1-deficient (146;147), the lipid raft internalization pathway,
however, still exists (148). Apparently, LPEI polyplexes could not efficiently transfect
HUH-7 cells via this route (Figure 35A). Since, however, BPEI successfully
transfected HUH-7 cells via both pathways (Figure 35B), differences between LPEI
and BPEI have to account for this effect.
Previously, it was proposed that the higher buffering capacity of branched PEI versus
linear PEI accounts for the fact that LPEI polyplexes can be found in – on average –
more acidic vesicles than BPEI polyplexes (149). According to the proton sponge
hypothesis, efficient vesicular buffering favors polyplex release into the cytosol. It
was therefore suggested that BPEI polyplexes escape early into the cytoplasm while
preventing sorting of the vesicles towards more acidic compartments (149).
Consequently when compared to LPEI complexes, BPEI polyplexes might be
released more easily from vesicles with a nearly neutral pH characteristic of the
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caveolae/raft-mediated pathway. This possibly made BPEI-mediated transfection
more susceptible to the inhibitor filipin.
Moreover, BPEI and LPEI polyplexes differ in their DNA binding activity. Binding of
DNA to BPEI is stronger than to LPEI (Julia Klöckner, unpublished observations)
impairing BPEI polyplex disassembly and thus reducing the amount of free plasmid
accessible to the transcription machinery. Due to this effect, BPEI polyplexes in
HUH-7 cells need both pathways for efficient transfection as the deletion of one
pathway probably reduces the intracellular available amount of transgene below the
minimum amount necessary for successful transfection. In contrast, LPEI polyplexes
seem to efficiently transfect cells even at reduced intracellular amounts of transgene,
since DNA is released more easily from the polyplexes making more DNA available
for transcription.
A further reason for the interference of filipin with BPEI polyplex- but not with LPEI
polyplex-mediated transfection in HUH-7 cells might rely on the different N/P ratios of
these formulations. Successful transfection by BPEI polyplexes with an N/P of 10
obviously does not require immediate vesicle acidification, whereas transfection by
LPEI polyplexes with an N/P of 6 does. Due to the high amount of PEI in these BPEI
polyplexes, the complexes probably have enhanced capability of disrupting the
membrane of vesicles with a neutral pH. This leads to the conclusion that not only
the type of PEI but also the amount of polycation in PEI polyplexes might influence
the route leading to successful transfection.
In HeLa cells, however, also transfection by LPEI polyplexes was affected by filipin
(Figure 35C). Most likely, cell type-related variations in intracellular vesicle
processing account for this effect.
Furthermore, the possibility has to be considered that the clathrin- and caveolae/raft-
dependent pathways interact at some point after internalization so that both
pathways are required for successful gene delivery. Although traveling between
caveosomes and endosomes has not been evaluated yet, some kind of interaction is
likely. Notably, colocalization of Alexa Fluor® 647 transferrin and Alexa Fluor® 488
CTB was found in both HUH-7 (data not shown) and HeLa cells (Karla de Bruin,
unpublished observations) already after approximately 1 h.
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5 Summary
Recently, PEG-shielded and EGFR-targeted polyplexes were designed for tumor-
directed gene transfer. In this thesis, the cellular mechanisms of EGFR-targeted
gene delivery were evaluated to obtain a detailed understanding of the processes
involved which is a key aspect for further improving the design of the vector.
EGFR-targeted PEGylated PEI polyplexes significantly enhanced transfection
efficiency into EGFR-expressing cell lines as compared to EGF-free PEGylated
complexes. Enhanced gene transfer efficiency was accompanied by a significant
increase in the number of transfected cells. No targeting effect, however, was evident
in cells devoid of EGFR or when the receptor was occupied by competing free ligand,
indicating that enhanced EGFR-targeted gene delivery is primarily mediated via a
ligand/receptor interaction. In addition to the established targeting system containing
murine EGF, also a polyplex formulation was generated containing human EGF.
Similar transfection efficiencies and targeting properties compared to mEGF(+)
polyplexes were obtained.
Increased cellular binding and accelerated uptake of EGFR-targeted polyplexes into
EGFR-expressing cells was identified as a substantial mechanism for improved gene
transfer efficiency. In line with this result, reporter gene expression upon EGFR-
targeted transfection was detectable much earlier than upon non-targeted gene
transfer. Cellular binding of EGFR-targeted polyplexes was further associated by
clustering of polyplexes into micrometer-sized particles, resembling typical receptor
clustering upon ligand binding.
In contrast to non-targeted polyplexes, EGFR-targeted polyplexes triggered EGFR
activation and initiation of the downstream signaling transducer Akt. Notably, EGFR
signaling is known to induce cell cycle progression and cell proliferation. Since
nuclear membrane breakdown during mitosis is known to facilitate nuclear polyplex
entry, the putative mitogenic effect of EGFR-targeted polyplexes is therefore another
feature possibly contributing to their enhanced transfection efficiency. Investigations
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however demonstrated that the EGF ligand was not capable of mediating enhanced
nuclear polyplex accumulation.
To further elucidate the process of EGFR-targeted gene delivery, the pathways
involved in cellular polyplex uptake were determined. Internalization of EGFR-
targeted polyplexes occurred via at least two endocytic pathways: 30 % entered the
cells via clathrin-dependent and 70 % via raft-dependent endocytosis. Despite
structural and biophysical differences of the polyplexes applied (LPEI, EGF(-) and
EGF(+)), this uptake pattern did not vary between the formulations, provided that the
particles were of similar size (approximately 80-200 nm). In contrast, internalization
of aggregated PEI polyplexes (LPEI, EGF(-)) proceeded via clathrin- and raft-
independent pathways, supporting the hypothesis that particle size is an important
factor determining the route of cellular polyplex entry.
In our model, successful transfection of the three polyplex formulations (LPEI, EGF(-)
and mEGF(+)) was predominantly mediated by the clathrin-dependent pathway,
emphasizing the relevance of vesicular acidification in intracellular trafficking of PEI-
based gene delivery systems. Nevertheless, depending on the cell type and the
polyplex formulation applied, also the caveolae/raft-dependent pathway was able to
mediate successful transfection. This was observed – in particular – when polyplexes
with a high N/P ratio (e. g. 10) were used. This indicates that different routes of
endocytosis can contribute to efficient transfection by PEI-based gene delivery
vectors.
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6.1 Abbreviations
AS-ON antisense oligonucleotides
ATP adenosine triphosphate
bp base pairs
BPEI branched PEI of 25 kDa
BSA bovine serum albumine
CLSM confocal laser scanning microscope
CMV cytomegalovirus
CN negative control
CTB cholera toxin subunit B
Da Dalton
DAPI 4,6-diamidino-2-phenylindole
DMEM Dulbecco´s Modified Eagle´s Medium
DMSO dimethyl sulfoxide
DNA deoxyribonucleic acid
DSP dual specificity phosphatase
DTT dithiothreitol
EDTA ethylenediaminetetraacetic acid
EGF epidermal growth factor
EGF(-) complexes EGF-free complexes
EGF(+) complexes EGFR-targeted complexes
EGFP enhanced green fluorescent protein
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EGF-PEG-PEI25 EGF covalently linked to BPEI via a
heterobifunctional 3.4 kDa PEG spacer
EGFR epidermal growth factor receptor
EGTA ethyleneglycol-bis-(aminoethylether)-tetraacetic acid
EPR enhanced permeability and retention effect
Erk extracellular-signal-regulated kinase
FBS fetal bovine serum
HBG HEPES-buffered glucose
HBS ½ HEPES-buffered glucose and HEPES-buffered
saline 1/1 (v/v)
HBS HEPES-buffered saline
HCC hepatocellular carcinoma
HEPES N-(2-hydroxyethyl)piperazine-N´-(2-ethanesulfonic
acid)
HSPG heparan sulphate proteoclycan
huEGF human EGF
huEGF(+) complexes EGFR-targeted complexes containing huEGF
JNK jun N-terminal kinase
kb kilo bases
Kd dissociation constant
kDa kilo Dalton
LB medium Luria Bertani medium
LPEI linear PEI of 22 kDa
LPEI polyplexes LPEI/DNA complexes, N/P 6
LSM (confocal) laser scanning microscope
Lys lysine
MAPK mitogen-activated kinase
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mEGF murine EGF
mEGF(+) complexes EGFR-targeted complexes containing mEGF
MKP MAPK phosphatase
MTT methylthiazol tetrazolium salt
MW molecular weight
n. d. not detectable
NHS-PEG-MAL α-Maleimide-ω-N-hydroxysuccinimide ester-
polyethylene glycol
NLS nuclear localization signal
NPC nuclear pore complex
N/P ratio molar ratio of PEI nitrogen to DNA phosphate
OM OptiMEM
PBMC peripheral blood mononuclear cells
PBS phosphate-buffered saline
pCMVLuc plasmid encoding luciferase under control of the
CMV promoter/enhancer
PEG polyethylene glycol
pEGFP plasmid encoding EGFP
PEG-PEI22 PEG of 20 kDa covalently attached to LPEI of
22 kDa
PEI polyethylenimine
PFA paraformaldehyde
PI propidium iodide
PI3-kinase phosphatidylinositol 3-kinase
PLL polylysine
PVDF polyvinylidene fluoride
RFU relative fluorescence units
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RLU relative light units
RNA ribonucleic acid
RTK receptor tyrosine kinases
SAPK stress-activated protein kinases
SCID severe combined immunodeficiency syndrome
SD standard deviation
SPDP succinimidyl 3-(2-pyridyldithio)propionate
siRNA small interfering RNA
TNBS trinitrobenzenesulfonic acid
Tris 2-amino-2-(hydroxymethyl)propane-1,3-diol
v volume
vmax maximum velocity
w weight
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